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Immunoglobulin G (IgG) is a complex glycoprotein that is largely being used in the 
development of antibody-based therapeutics to treat a variety of diseases such as cancers, 
autoimmune diseases, and infectious diseases. A major challenge in developing such therapeutics 
originates from the heterogeneity of the Asn297 glycan of IgG. This sugar part (Asn297 glycan) 
of IgG has been shown to play an important role in the antibody properties such as antibody 
stability, effector functions, solubility, pharmacokinetics, and immunogenicity. To study the 
effect of Asn297 glycan composition on the properties of the human IgG2 (a preferred IgG 
subclass for developing antibody-based therapeutics when the antibody effector functions are not 
required), we developed an approach to produces homogeneous IgG2 Fc glycoforms. Studying 
these homogeneous IgG2 Fc glycoforms suggested that enriching the core fucose within IgG2 
Asn297 glycan could add more advantages to developing IgG2-based therapeutics by providing 
more reduction in any possible undesirable effector functions of these therapeutics. The in vitro 
enzymatic synthesis developed here also enabled studies of different glycosylation sites 
accessibility to glycosyltransferase and expanded our understanding of the glycosylation 
heterogeneity. The Asn297 glycan also offers a great opportunity in developing antibody drug 
conjugates (ADCs), a therapeutic modality where a toxic payload is conjugated to IgG. The early 
ADC development relied on conjugating the payload non-specifically through either the lysine or 
cysteine residues of IgG using conventional chemistries. Producing ADCs in this way, results in 
heterogeneous products. ADC heterogeneity usually translates into poor pharmacokinetics, 
stability, and efficacy. In this work, we developed a chemoenzymatic synthesis platform to 
functionalize the Asn297 glycan in a novel way and use it as a specific site for conjugation. The 




on IgG2 Fc. This approach enabled us to produce conjugates with excellent homogeneity. 
Subsequent studies of these conjugates showed the utility of the approach followed here in 
making of site-specific conjugates with good properties and the possibility of following this 
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Therapeutic monoclonal antibodies: An overview 
 Therapeutic monoclonal antibodies (mAb) represent one the fastest growing classes of 
pharmaceutical products with more than 60 approved by the United States FDA as of May, 2016. 
This rapid growth of therapeutic mAb as well as mAb-derived products will result in worldwide 
sales of about $94 billion by 2017 (compared to $75 billion in 2013 which represented nearly 
half of the total sales of all biopharmaceutical products).
1,2
 Therapeutic mAb have been utilized 
in treating a wide variety of diseases and clinical conditions including infectious diseases, 
cancers, allergies, inflammatory diseases, and cardiovascular diseases.
3
 Therapeutic mAb have 
the advantage of binding their targets in a specific manner which can result in fewer side effects 
than conventional pharmaceutical products. The high specificity of mAb toward certain antigens 
also enabled the use of these biotechnology products as vehicles to deliver other compounds 
(usually toxins) to cells expressing these antigens, such as in making of antibody drug conjugates 
(ADCs).
4,5
 Also, the long biological half-life of mAb is a unique feature of this class of 
biopharmaceutical products and enables a high efficiency and reduced dose frequency of mAb 
making them more convenient in treating chronic diseases.
3,6
  
 Monoclonal antibodies were first generated successfully by Kohler and Milstein in 1975 
when they used hybridoma technology to produce “antibody of predefined specificity”.
7,8
 Soon 
after this success, which led to Nobel Prize, mAb became widely used in clinical laboratories as 
indispensable biological tools in the diagnosis of many pathological conditions. At the same 
time, interest was growing in making therapeutic mAb to treat certain diseases, especially cancer. 
Early trials to make therapeutic mAb were not successful because most of these mAb produced 
by hybridoma technology were of murine origin.
3,9–11
 Administration of murine mAb to humans 




response (HAMA) results in reducing the effectiveness of the mAb and can range from mild 
allergic reactions, such as rash, to more severe reactions resulting in renal failure. In 1985, the 
first therapeutic mAb, Orthoclone OKT3 (muromonab-CD3), was approved by the FDA for the 
prevention of allograft rejection in renal transplantation. Orthoclone OKT3, a mouse IgG2a 
produced by hybridoma technology, was continued to be used until 2010 when it was voluntarily 
withdrawn from the market following subsequent advances in transplant medicines.
12
  
 Started by mid-1980 and taking advantage of the improvement in the fields of molecular 
biology and protein engineering, several strategies have been introduced to improve the 
characteristics of therapeutic mAb produced initially by hybridoma technology from murine 
plasma cells.
3,13,14
 Most of these strategies were based on the rationale of reducing the extent of 
mouse amino acid sequence within the antibody (antibody humanization) in order to minimize 
any potential immunogenicity associated with injecting these antibodies into the human body. In 
one strategy, part of the variable domains amino acid sequence of a mouse-derived antibody is 
converted into the corresponding amino acid sequence of a human antibody. This strategy is used 
to produce a mAb containing as much human antibody amino acid sequence as possible such as 
in the production of chimeric (about 65% human) and humanized (about 95% human) antibodies. 
In other strategies, the produced mAb contains 100% human-derived amino acid sequence 
(human antibody) and this can be achieved through the use of certain technologies such as 
phage-display and transgenic-mouse technologies. These advanced technologies as well as the 
development in mAb production and purification resulted in more successful production and 
commercialization of mAb and the emergence of the therapeutic mAb class as a rapidly growing 





Structure of human IgG and Asn297 glycan heterogeneity 
Immunoglobulin G (IgG) antibody is a soluble glycoprotein secreted by B cells and 
plasma cells and represents a major component of the humoral immunity. IgG is the most 
abundant immunoglobulin isotype in the human serum and comprises about 75% of the total 
serum immunoglobulins.
15
 All of the currently marketed therapeutic monoclonal antibodies are 
of IgG isotype. IgG is a Y- shaped multifunctional glycoprotein that is made up of four 
polypeptide chains, two identical heavy chains and two identical light chains, to form three 
structurally independent protein moieties (two Fab regions  and one Fc region) connected 
through a flexible hinge region (Figure 1).
15–17
 The heavy chain consists of one variable domain 
(VH) followed by a constant domain (CH1), a hinge region amino acid sequence, and two more 
constant domains (CH2 and CH3); while the light chain consists of one variable (VL) domain and 
one constant (CL) domain. The antigen-binding fragments (Fab) define the antibody-specificity 
against certain antigens by adapting a specific amino acid sequence within their complementary 
determining regions (CDR). The fragment crystallizable (Fc) of the antibody is responsible of 
mediating the antibody effector functions and antibody recycling through specific set of Fc-
receptors and Fc-binding proteins.
18,19
  
 IgG isotype contains a well conserved N-glycan at Asn297 (Eu numbering) in the CH2 
domain of the Fc region which is critical for the structure and function of the antibody. In 
addition to the Asn297 glycan, about 20% of the human IgG pool contains N-linked glycans in 
the Fab region.
20,21
 Also, certain IgG3 and IgG2 allotypes contain an extra N-linked glycan at 
Asn392 in the CH3 domain of the Fc region. The structure of Asn297 glycan is variable but in 






 All of these types share the same pentasaccharide core structure however 
they vary in the number and type of sugar units at their non-reducing termini.  
 
Figure 1. Diagrammatic representation of immunoglobulin G (IgG) molecule. 
In high mannose N-glycans, the non-reducing termini are composed of only mannose 
sugar residues. In hybrid type N-glycans, some of the non-reducing termini are composed of 
mannose while other termini are composed of GlcNAc, galactose, or sialic acid. In complex type 
N-glycans, none of non-reducing termini are composed of mannose.
24
 Asn297 glycan is mostly 




 Being an N-liked glycan, the Asn297 glycan biosynthesis follows the same biosynthetic 
pathway of mammalian N-glycosylation (Figure 3).
24,25




of many steps that can occur in different compartments of the cell. Protein N-glycosylation 
begins by en bloc transfer of the glycan precursor Glc3Man9GlcNAc2 from dolichol-p-p-
Glc3Man9GlcNAc2 to Asn residue of the N-glycosylation sequon (NXT/S) of the nascent 
polypeptide chain.  
 
Figure 2. Major types and structure of N-linked glycans. 
The transfer takes place inside the lumen of the endoplasmic reticulum and catalyzed by 
the enzyme oligosaccharyltransferase (OST). The three glucose units of Glc3Man9GlcNAc2 were 
then cleaved off by α-glucosidases to form a high mannose glycan Man9GlcNAc2 (Man9) and the 
protein is properly folded at this stage. The Man9 glycoprotein is then translocated to the Golgi 
apparatus for more processing of the oligosaccharide. The Golgi apparatus contains different 
glycosidases and glycosyltransferases localized at different compartments within its lumen. In 




produce a Man5GlcNAc2 (Man5) glycan. In the medial-Golgi, N-acetylglucosaminyltransferase-I 
(GnT-I) transfers GlcNAc from the activated nucleotide sugar UDP-GlcNAc to the Man5 glycan 
to form the hybrid glycan GlcNAcMan5GlcNAc2. UDP-GlcNAc and other activated nucleotide 
sugars are pumped into the Golgi lumen via the assistance of Golgi-bound nucleotide sugar 
transporter proteins. The hybrid glycan then becomes a substrate for mannosidase II which 
hydrolyzes two more mannose residues to prepare the glycan for N-








Figure 3. Schematic overview of the mammalian N-glycosylation pathway taking place in the 
endoplasmic reticulum (ER) and the Golgi apparatus. 1) Oligosaccharyltransferase (OST). 2, 3) 
α-glucosidases. 4) α1,2-mannosidases. 5) N-acetylglucosaminyltransferase-I (GnT-I) plus UDP-
GlcNAc. 6) Mannosidase II. 7) N-acetylglucosaminyltransferase-II (GnT-II) plus UDP-GlcNAc 
and α1,6-fucosyltransferase (FUT8) plus GDP-fucose. 8) Galactosyltransferases plus UDP-





Monoclonal antibodies modes of action 
 There are several modes by which IgG antibody and hence therapeutic mAb can exert 
their therapeutic effects especially in treatment of cancers (Figure 4).
26–28
 Some of these modes 
of action rely on the binding of the Fc part of the antibody engaged in the immune complex 
(antibody-antigen complex) with the complement system C1q protein and Fcγ receptors. 
Interestingly, antibody binding to this protein and these receptors is highly affected by the 
glycosylation profile of the Asn297 glycan.
16,29,30
 Other modes rely on just binding of the 
antibody through its Fab region to either a receptor or a ligand and hence block the receptor-
ligand interaction and prevent subsequent biological effect. Also, antibodies can be used as 
carriers to deliver cytotoxic payloads to certain cells to obtain certain pharmacological effects, 
such as in antibody drug conjugates (ADCs) which are used mainly to treat cancers.
4
 
Combination of modes of action can also happen after binding of the antibody to its target and 
below is a description of each mode: 
Antibody effector functions 
Many antibody effector functions are mediated through Fcγ receptors. Human Fcγ 
receptors represent an important class of closely related receptors that can bind human IgG 
isotype through the Fc region.
18,31
 These receptors are widely distributed on the surface of 
different immune cells and clustering of these receptors on the surface of the immune cell can 
either activate the cell such as in the case of clustering of FcγRI, FcγRIIa, FcγRIIc, and FcγRIIIa 
or inhibit the cell such as in the case of clustering of FcγRIIb. The activating Fcγ receptors 




or their adaptor protein, while the inhibitory receptor (FcγRIIb) contains an immunoreceptor 





Figure 4. Therapeutic monoclonal antibodies possible modes of action. a) Activation of antibody 
dependent cellular cytotoxicity (ADCC). b) Activation of complement dependent cytotoxicity 
(CDC). c) Activation of antibody-dependent cell-mediated phagocytosis (ADCP). d) Antibody 
drug conjugates (ADC) mediated cytotoxicity. e) Blocking receptor-ligand interactions and 






Among this class of receptors, FcγRIIIa has gained a particular attention in the design 
monoclonal antibodies with enhanced cytotoxic effect. FcγRIIIa is expressed on the surface of 
monocytes, dendritic cells, macrophages, and natural killer (NK) cells. FcγRIIIa is the sole 
receptor expressed on the surface of natural killer (NK) cells; however recent studies showed that 
about 20% of the population expresses FcγRIIc as well.
34
 Clustering of FcγRIIIa on the surface 
of NK cells induces a powerful cytotoxic effect called antibody-dependent cellular cytotoxicity 
(ADCC).
16,27
 During ADCC, the NK cell releases cytokines that mediate the lysis of the target 
cells that are brought to its proximity through the binding with IgG. There have been many 
antibody engineering approaches to increase the binding of the antibody to FcγRIIIa and hence 
the induction of more powerful ADCC. Some approaches involved changing of the antibody 
amino acid sequence while others involved glycoengineering of the Asn297 glycan, as it will be 
discussed later in this chapter.
35–39
 Also, FcγRIIIa has a polymorphism at position 158 which 
results in two receptor variants, FcγRIIIa-V158 and FcγRIIIa-F158 that are different in their 
binding affinity to IgG subclasses. The valine variant of the receptor has a stronger binding 
affinity to IgG than the phenylalanine variant. This functional polymorphism has also been 
shown to affect the therapeutic efficacy of therapeutic mAb (such as rituximab) in different 
patients where patients who were homozygous for the valine variant of the receptor showed a 
higher therapeutic response.
40,41
 The other receptor that plays an important role in antibody 
effector functions is FcγRIIa. This receptor is present on the surface of many phagocytic cells 
and can mediate a phagocytic effect called antibody-dependent cell-mediated phagocytosis 
(ADCP) through which the antibody-bound antigen is engulfed and destroyed by the phagocytic 
cell.
35,42,43
 This receptor also exhibits two variants, FcγRIIa-H131 and FcγIIa-R131, which have 




 Antibody can also activate the complement system through the classical pathway of 
activation of this system and results in mediating complement dependent cytotoxicity 
(CDC).
19,28,36
 The complement system is part of the innate immune system which complements 
the ability of the antibodies and phagocytic cells to clear pathogens from the human body. In this 
mode of action, the antibody engaged in the immune complex binds the soluble component of 
the complement system, C1q protein. This binding induces conformational changes within the 
protein which lead to a cascade of proteolytic reactions and activation of other complement 
components such as the C4a that acts as an anaphylotoxin and activate the inflammatory cells. 
Also, activation of the complement system will eventually result in the formation of the 
complement membrane attack complex (MAC) which can insert itself in the membrane of the 
target cell and form a porous channel and induces cell lysis and death. Although the complement 
system plays an important role in protecting the body from foreign pathogens, its activation can 
also result in observed side effects of antibody therapeutics.
44,45
 In addition, the role of CDC in 
the clinical effectiveness of some anticancer mAb, like rituximab, is not well confirmed, and it 
has been shown that there is no clear correlation between the therapeutic response of this mAb 
(rituximab) and its ability to induce CDC.
46
   
Antibody blocking activities 
Antibodies can also intercept a receptor-ligand interaction and block any undesirable 
biological effects that can result from this interaction.
26,27
 The antibody can be designed to bind 
the receptor on the surface of the cell and block the ligand binding site. Also, the antibody can be 
designed to bind a receptor at different site than the ligand binding site; however upon binding, 
the antibody will induce conformational changes in the receptor to prevent its interaction with 




the dimerization domain of the receptor such as in case of antibody designed to block ligand 
binding to epidermal growth factor (EGF) receptor.
11,47
 Alternatively, the antibody can be 
designed to bind the ligand (instead of the receptor) and sterically prevent it from binding to its 
receptor and thus block the signal. Intercepting a receptor-ligand interaction can be well 
explained in the context of designing checkpoint blockade antibodies.
48
 The checkpoint blockade 
antibodies, also called immune checkpoint inhibitors, are a class of mAb designed to treat cancer 
utilizing a novel mechanism of action by targeting activation of the immune effector cells. These 
mAb are designed to block certain receptors on the surface of T-cells, such as programmed cell-
death protein (PD-1) and cytotoxic T-lymphocytes antigen 4 (CTLA-4). Binding of the natural 
ligands to these receptors causes inactivation of the T-cells, an immune regulatory mechanism 
that prevents the destruction of self-antigen and developing of autoimmune diseases. However, 
the cancer cells can use this mechanism to evade the immune system by overexpressing these 
ligands and thus shutting down the T-cells. Therefore, an immune checkpoint inhibitor mAb can 
reverse this inhibitory action and restore the activity of T-cells. Some antibodies were designed 
to bind PD-1 receptor such as pembrolizumab for the treatment of melanoma.
49
 Other antibodies 
were designed to block CTLA-4 receptor such as ipilimumab, which is also used for the 
treatment of melanoma. Immune checkpoint inhibitor mAb were also designed to bind to PD-1 
ligand (PD-L1), which can be overexpressed on the surface of the tumor cell, such as the 




 Antibody drug conjugates 
Antibodies can be also used as carriers in the design of antibody drug conjugates 
(ADCs).
5,27




mAb component of the ADC. In general, ADC combines the cytotoxic effect of the toxic 
payload with the specificity of the mAb to target certain tumor cells. Also, the mAb part of the 
ADC reduces the clearance of the conjugate through the interaction of the Fc region with the 
neonatal Fc receptor (FcRn), which is an essential receptor playing a critical role in re-shuttling 
the antibody back to the extracellular fluids and prevent its lysosomal degradation inside the 
cell.
51
 When designing ADC, the mAb component is designed to target antigen with certain 
criteria.
52,53
 Target antigen should have high levels of expression on the surface of the tumor cell 
and should also undergo rapid and efficient internalization upon binding with the ADC to deliver 
sufficient amount of the toxic payload to the inside of the tumor cell. The payload should be a 
highly toxic drug that can result in death of the tumor cell upon delivery by ADC. There are 
several toxic drugs that can be used in making ADCs such as monomethyl auristatin E (MMAE), 
which inhibit the polymerization of tubulin; maytansines, which inhibits the assembly of 
microtubules; calicheamicin which cleaves the DNA strands; and pyrrolobenzodiazepines, which 
are DNA minor groove cross-linkers.
53
 All of these drugs can inhibit the tumor cell proliferation 
and result in programmed cell death. Most of these drugs are hydrophobic in nature and this 
hydrophobicity could help the drug in escaping the lysosomal degradation upon internalization of 
the ADC and allow it (the drug) to diffuse out to the site of action.
54
 ADCs should be designed 
carefully to prevent any deterioration in the mAb selectivity, internalization efficiency, 
pharmacokinetics, and physicochemical properties upon conjugation of the payload.
55,56
 The 
right conjugation site and right drug to antibody ratio (DAR) coupled with the right conjugation 
chemistry and linker technology should minimize any negative effect on the ADC properties and 







Human IgG subclasses and the design of therapeutic monoclonal antibodies 
 Human IgG isotype is a major immunoglobulin isotype present in the serum and 
constitutes about 10-20% of the total serum protein. This immunoglobulin isotype comprises 
four subclasses, IgG1, IgG2, IgG3, and IgG4.
15,16,59
 These IgG subclasses have different amino 
acid sequence within the constant region of their heavy chains. Although, these subclasses share 
about 90% amino acid sequence homology, the minor difference in their structure gives each 
subclass unique features that can be significantly different from the other (Table I). Most of the 
amino acid sequence difference lies in the hinge region and the upper CH2 domain of the 
antibody, although there are minor differences in other regions. The difference in the properties 




IgG1 is the most abundant subclass and counts for about 67% of the total serum IgG 
pool.
15,59
 This subclass plays an important role in the humoral immunity since it is the major IgG 
subclass and usually produced in response to soluble protein and membrane protein antigens. 
Most of therapeutic mAb, especially antitumor mAb, are of IgG1 subclass because this subclass 
is a strong activator of the ADCC and CDC. The biological half-life of IgG1 (as well as IgG2 
and IgG4) is approximately 21 days and such long half-life is advantageous when designing 
mAb intended to treat chronic diseases such as cancer and autoimmune diseases.
6
  
The second most abundant IgG in human serum is IgG2 which constitutes about 22% of 
the total serum IgG pool. Human body usually develops IgG2 antibody response when the 
immune system recognizes antigens of carbohydrate composition especially bacterial 
polysaccharide antigens.
15,16




only two. Recently, IgG2 disulfide bonds have been shown to undergo rearrangement.
61–64
 As a 
result of this disulfide bonds rearrangement, IgG can exist in three different isoforms. It is 
believed that this flexibility in the hinge disulfide bonds could also give IgG2 the ability to exist 
in dimers with a possible increase in the antibody avidity against pathogens.
65
 As shown in Table 
I, IgG2 binds weakly to most of Fcγ receptors except FcγRIIa. FcγRIIa undergoes a 
polymorphism at amino acid number 131 to result in two receptor variants, FcγRIIa-H131 and 
FcγRIIa-R131. 





IgG2 IgG3 IgG4 
Serum % 67 22 7 4 
Serum concentration (mg/ml) 8 2.5 0.8 0.4 
Size (kDa) 146 146 170 146 
No. of hinge disulfide bonds 2 4 11 2 
Half-life (days) 21 21 7 21 
No. of allotypes 4 2 13 1 
C1q binding ++ + +++ - 
FcγRI binding +++ - ++++ ++ 
FcγRIIa-H131 +++ ++ +++++ ++ 
FcγRIIa-R131 +++ + +++++ ++ 
FcγRIIIa-V158 +++ + +++++ ++ 
FcγRIIIa-F158 ++ - +++++ - 
FcγRIIb + - ++ + 
      
         
Interestingly, human IgG2 subclass has different affinities to these two receptor variants where it 
has a higher affinity for the FcγRIIa-H131 variant than the FcγRIIa-R131.
66–68
 This receptor 




diseases such as systemic lupus erythematosus (higher incidence in R131 variant expressing 
individuals), ulcerative colitis (higher incidence in H131 variant expressing individuals), and 
malaria (higher incidence in H131 variant expressing individuals).
69–71
 The susceptibility to these 
diseases could suggest a possible role for IgG2 subclass in the pathogenesis of these diseases. 
IgG2 is also known to have a weak binding affinity to C1q protein and thus a low ability to fix 
the complement system and induce CDC. The low effector functions of IgG2 subclass has been 
utilized in designing therapeutic mAb where only an antibody blocking effect is required for the 
mAb mechanism of action. However, the low affinity of IgG2 subclass to the inhibitory FcγRIIb 
may counteract its low affinity to the activating Fcγ receptors when both receptors are expressed 
on the same immune effector cell. Nonetheless, there are several IgG2-based mAb that are 
currently in the market such as denosumab and panitumumab which are used for treating 
osteoporosis and colorectal cancer, respectively.
72–74
  
IgG3 subclass of human IgG isotype constitutes about 7% of the total serum IgG pool 
and characterized by a very long hinge region which contains eleven disulfide bonds (Table I).
15
 
In general IgG3 immune response is mediated during viral infections and it is usually 
accompanied by IgG1 response even though IgG3 appears first in the course of the 
infection.
15,16,59
 IgG3 is characterized by having a shorter biological half-life (about 7 days) 
compared to the other IgG subclasses (IgG1, IgG2, and IgG4) which have relatively long 
biological half-lives (about 21 days).
75
 Also, IgG3 has the largest number of allotypes among the 
other IgG subclasses.
16,59,76
 Most of IgG3 variants have N-glycosylation site in the Fc region at 
Asn392 in addition to the well conserved N-glycosylation at Asn297. IgG3 subclass has a strong 
ability to activate the complement system and it also has a strong ADCC activity which can be 




this subclass has not been utilized yet to make therapeutic mAb probably because of its relatively 
short biological half-life and its long hinge region which makes it more prone to proteolysis.
59
  
IgG4 is the least abundant IgG subclass in human serum and constitutes only about 4% of 
the total serum IgG pool.
15,77
 The immune system produces IgG4, in addition to IgG1 and IgE, in 
response to allergens, especially after a repeated or a long term exposure. Also, IgG4 represent 
the dominant immune response to therapeutic proteins such as factor VIII and factor IX.
16
 Like, 
IgG1, IgG4 has only two disulfide bonds in the hinge region. However, IgG4 undergoes a 
phenomenon called Fab arm exchange where the antibody can dissociate into two half-molecules 
under certain redox conditions.
77,78
 Then, half-molecules from IgG4 having different specificities 
can recombine to result in the formation of a bispecific IgG4 molecule. The susceptibility of 
IgG4 to this phenomenon has been shown to be due to the presence of serine at position 228 in 
the hinge region instead of proline in the other subclasses. This mutation makes the hinge more 
flexible and allows easier disulfide bonds rearrangement within the hinge region. The presence 
of arginine at position 409 in IgG4, instead of lysine in IgG1, weakens the CH3-CH3 hydrophobic 
interaction and also allows the molecule to undergo Fab arm exchange. IgG4 is the weakest 
activator of the complement system and also it has weak affinities to Fcγ receptors (Table I). 
Hence, IgG4 has low Fc-mediated effector functions. Likewise IgG2, IgG4 has been utilized in 
making therapeutic mAb when the effector functions are not part of the mAb mode of action.
59,79
 
However, in one trial IgG4-based anti-CD28 monoclonal antibody (TGN1412) caused a serious 
adverse effect where six patients developed cytokines storm during clinical trials in 2006.
80
 It has 
been believed that the susceptibility of IgG4 to Fab arm exchange was behind the development 
of this adverse effect. Recent IgG4-based mAb were engineered to have S228P mutation to 




successfully for treatment of a variety of diseases such as pembrolizumab, an immune 




Importance of Asn297 glycan for therapeutic monoclonal antibodies  
 Asn297 plays an important role in stabilizing the antibody peptide backbone by making a 
series of unique interactions with the amino acids in the CH2 domain of the antibody. The 
hydrophilic nature of this glycan also helps in masking the hydrophobic amino acid residues in 
this domain and maintaining proper native IgG conformation.
30,83,84
 Removal of the Asn297 
glycan reduces the thermal stability of IgG1 and increases the aggregation propensity in many 
occasions.
85–87
 It has also been shown that Asn297 glycan increases the solubility of IgG1 where 
deletion of the Asn297 glycosylation site by site-directed mutagenesis reduces the solubility of 
the non-glycosylated IgG1 Fc compared to the natural IgG1 Fc that is glycosylated at Asn297.
85
 
However, the solubility of the antibody may not always increase by having extra glycans and a 
reverse effect (i.e. reduced solubility) may also occur. The latter scenario can be seen in 
cryoimmunoglobulins where the decreased solubility of these immunoglobulins was shown to be 
associated with the antibody having extra N-glycans at certain sites in the Fab region.
88
  
 The antibody effector functions are highly dependent on the Asn297 glycan and removal 
of this glycan results in a dramatic reduction of in these effector functions such as reduction in  
antibody dependent cellular cytotoxicity (ADCC), antibody dependent cellular phagocytosis 
(ADCP), and complement dependent cytotoxicity (CDC).
30,89
 The reason behind this reduction is 
that Asn297 is required to maintain a specific protein conformation in the CH2 domain. The 




to the receptors and proteins that mediate these effector functions. The composition of the 
Asn297 glycan also plays an important part in fine-tuning these effector functions. It has been 
shown that the absence of core fucose increases the binding to FcγRIIIa with subsequent increase 
in IgG1-mediated ADCC by 50-100 folds.
90–94
 The reason for this reduced affinity has been 
shown to be due to core-linked fucose interrupting glycan-glycan interactions that are present 
between non-fucosylated IgG1 and the N-linked glycans of Asn162 on FcRIIIa. This finding 
has sparked a tremendous interest in modifying the Asn297 glycan of IgG1 for designing better 
therapeutic mAb.
92
 The presence of bisecting GlcNAc within the structure of Asn297 glycan has 
also been shown to increase ADCC, however this effect is most probably related to the absence 
of core fucose since bisecting GlcNAc hinders the addition of core fucose by α1,6-
fucosyltransferase (FUT8).
91
 The effect of galactose on the antibody effector functions is still not 
completely understood. The presence of terminal galactose in the structure of Asn297 glycan 
increases the antibody binding to C1q protein and activation of the complement system through 
the classical pathway to result in higher CDC.
95
 Galactose has also been shown to be implicated 
with some autoimmune diseases where the level of Asn297 glycan galactosylation is reduced in 
these diseases such as rheumatoid arthritis (RA). Interestingly, women who have RA show an 
increase in the level of galactosylation when they become pregnant and go through a period of 
remission of RA symptoms.
96
 Terminal sialic acid has been shown to make the antibody have 
anti-inflammatory effect. However, the anti-inflammatory effect of the sialylated IgG is not fully 
understood.
89,95,97
 Many studies have been carried out with an attempt to correlate this effect with 
the antibody binding to Fcγ receptors as well as some other receptors such as Dendritic Cell-




outcomes of these studies were conflicting and therefore more studies are needed to understand 
the role of sialic acid on IgG properties.
97–99
 
 The composition of the Asn297 glycan plays an important role in the antibody 
pharmacokinetics.
23
 In general, IgG has a long biological half-life of about 21 days and this long 
half-life of this glycoprotein is attributed to the FcRn-recycling mechanism of IgG.
51
 In this 
recycling mechanism the FcRn receptor binds tightly to the antibody at the CH2-CH3 domains 
interface at low pH that is characteristic of the lysosome environment and prevents the release of 
the antibody for lysosomal degradation. At the same time the receptor shuttles the antibody to the 
surface of the cell and releases it at the neutral extracellular environment where the affinity of 
binding is low. Added to that, the big size of the IgG (about 150 kDa) reduces the glomerular 
filtration and clearance of the antibody by the kidneys.
6
 Although the Asn297 glycan does not 
affect the binding of IgG to FcRn and hence does not play a role in the FcRn-recycling 
mechanism, the type of the Asn297 glycan has been shown to affect the pharmacokinetics of IgG 
through other mechanisms. The high mannose glycoforms are cleared more rapidly from the 
blood due to increased binding to mannose receptors and uptake by cells that express these 
receptors.
100
 Sialylated glycoforms have decreased clearance and longer biological half-lives due 




Recently, two therapeutic mAb were developed through glycoengineering of the An297 




 which were 
approved in 2012 and 2013, respectively. The first mAb was expressed in a FUT8 knockout 
strain of Chinese hamster ovary (CHO) cells to block the addition of core fucose by FUT8 to the 




functions such as ADCC. The second mAb, obinutuzumab, was expressed in a cell line 
overexpressing the bisecting GlcNAc to again prevent the addition of core fucose to the Asn297 
glycan by FUT8. In addition to these two technologies, many other approaches have been 
developed to reduce the amount of core fucose on the Asn297 glycan of IgG such as feeding the 
host cells with the fucose analogue, 2-Deoxy-2-fluoro-L-fucose, to inhibit FUT8.
105
 Other 
approaches relied on the expression of the antibody in FUT8 null expression hosts such as the 
yeast Pichia pastoris.
106
 Finally, glycoengineering represent an elegant approach to produce 
better therapeutic antibodies and the more understanding of the role of each glycoform on the 
antibody stability, function, immunogenicity, and pharmacokinetics, the faster the development 
of next generation therapeutic mAb.  
Conclusions 
Glycosylation of therapeutic mAb represent a unique posttranslational modification that 
has a high degree of heterogeneity as glycosylation is not a template-driven process.
24,25
 The 
heterogeneity of this glycan is represented by the formation of different glycan types (high 
mannose, hybrid, and complex), presence or absence of core fucose, galactose, sialic acid, and 
bisecting GlcNAc, as well as glycosylation site occupancy.
22,23
 The resulting heterogeneity of 
Asn297 glycan of human IgG isotype, especially IgG1 subclass, has been shown to have a 











. Therefore, monitoring the 
composition of this glycan is critical to ensure that mAb has a consistent glycosylation profile 
among the different production batches. At the same time, glycoengineering the mAb to have 
enriched Asn297 glycan of certain composition provides a big chance to produce therapeutic 






Chapter 2 aims: To develop a platform for the synthesis of homogeneous and well-defined 
IgG2 Fc glycoforms on a relatively large laboratory-scale using a combination of glycosylation-
deficient host, purification methods, and in vitro enzymatic synthesis. The produced IgG2 Fc 
glycoforms were to be studied for the effect of the structure of Asn297 glycan, especially the 
effect of core fucose, on IgG2 properties to ultimately create better IgG2-based therapeutic 
modalities. 
Chapter 3 aims: To modify the Asn297 glycan of IgG2 beyond the natural sugar composition 
and introduce a modified sugar with a bioorthogonal handle to allow a unique site-specific 
conjugation through Asn297 glycan. The functionalized IgG2 Fc having a site-specific 
biorthogonal handle was to be conjugated with three alkyne-PEG linkers having different 
physicochemical properties and studies of the resulting conjugates, head to head, for the effect of 
these linkers on IgG2 Fc properties. 
Chapter 4 aim: This final chapter summarizes the statement of the problem, the conclusions 
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Production of IgG2 Fc with core-linked fucose and studies of its effects on 





 The immunoglobulin G (IgG) class of antibody is the prevalent immunoglobulin (Ig) 
isotype in blood and is responsible for a wide range of systemic immune responses.  In humans, 
the IgG isotype is made up of four subclasses, IgG1, IgG2, IgG3, and IgG4, which are numbered 
to reflect decreasing amounts in serum, such that IgG1 is present in the highest concentration and 
IgG4 the least.
1,2
 The four human IgG subclasses are highly homologous, but differences in the 
heavy chain sequences of their constant and hinge regions result in a range of effector functions 
that can adapt antibody-dependent immune responses to different pathogens.  Human IgG2 is the 
second most abundant IgG in serum and has been found to have distinct properties from the more 
studied IgG1 subclass. In general, IgG2 has the weakest interaction of the subclasses with Fc 
receptors that direct cellular immune responses, and it has the second weakest ability to activate 
complement for complement-dependent cytotoxicity. Even though IgG2 is thought to have weak 
effector functions, IgG2 antibodies are associated with immune responses to bacterial 
polysaccharide antigens, and deficiencies of the IgG2 subclass have been associated with 
susceptibility to bacterial infections.
3–6
 Like IgG1, IgG2 is glycosylated on Asn297 (Eu 
numbering) 
1,7,8
 in the Fc region CH2 domain and this N-linked glycosylation is important for 
antibody stability and essential to most immune responses directed by IgG2 antigen binding.
9,10
 
Because of IgG2's properties, it is an attractive subclass for the development of monoclonal 
antibody therapeutics where blocking of targets by binding but weaker effector functions are 
desired. There are currently only two human IgG2-based monoclonal antibodies (mAb) in use 
clinically, panitumumab and denosumab.
11–13
  
 Core-linked fucosylation of N-linked glycans in the IgG class of antibodies has been 
shown to act as a modulator of IgG effector functions.
14




interactions of the IgG class of antibodies with Fc receptor IIIa (FcRIIIa), which is a receptor 
involved in directing antibody dependent cellular cytotoxicity (ADCC) of many immune cells 
and the only Fc receptor found on most human natural killer cells (NK cells).
15
 The effects of 
core-linked fucosylation on interactions with FcRIIIa have been best studied in the IgG1 
subclass, where the presence of fucose has been shown to reduce IgG1 affinity for FcRIIIa by 
up to 50-fold
14,16–19
 and thereby decrease ADCC activity of FcRIIIa expressing immune cells.  
The reason for this reduced affinity has been shown to be due to core-linked fucose interrupting 
glycan-glycan interactions that are present between non-fucosylated IgG1 and the N-linked 
glycans of Asn162 on FcRIIIa.
18,19
 Since the absence of core-linked fucosylation on IgG1 
significantly increases ADCC, there has been much effort to develop methods to produce non-
fucosylated antibodies with increased ADCC activity for use as therapeutics where strong 
effector functions are desired.
20
 The addition of core-linked fucose to N-glycans is mediated by a 
single enzyme, -1,6-fucosyltransfurase 8 (FUT8) in mammals.
21,22
 The production of antibodies 
in cell lines with FUT8 deleted will result in non-fucosylated antibodies with increased ability to 
direct ADCC, and such cell lines have been utilized to produce therapeutic mAb.
23
   
 Since the use of the IgG2 subclass as a therapeutic currently focuses largely on IgG2's 
reduced ability to direct effector functions, we were interested in studying the effect of the 
presence of core-fucosylation on IgG2 rather than its absence.  These studies were hampered to 
some extent by the necessity of producing fully fucosylated IgG2 Fc and by the presence of 
glycoprotein microheterogeneity in glycoproteins produced in common cell lines.
24–28
 
Glycoprotein microheterogeneity, such as incomplete core fucosylation, presents a substantial 
barrier to the study of the function of protein glycosylation.  Assays of glycoform mixtures in 




mixture can respond differently.  This problem can be exacerbated when the presence of a 
contaminating glycoform, such as a non-fucosylated IgG, gives a stronger signal in an assay such 
as receptor binding than the fucosylated glycoform under study.
14,16,18,19
 For this reason, it is 
desirable to conduct experiments on samples as close to homogeneous as can be practically 
achieved.  Thus to study the effects of core fucosylation on IgG2 Fc we developed methods to 
produce homogeneously core-fucosylated IgG2 Fc on relatively large laboratory-scale as part of 
a larger project to produce a wide range of homogeneously glycosylated glycoproteins to 
facilitate glycobiology studies. 
N-linked glycoprotein biosynthesis can result in the formation of a large number of 
possible high mannose, hybrid and complex glycoforms due to branching pathways, competing 
reactions and incomplete processing. Nonetheless, many glycoproteins contain only a specific 
subset of the possible N-glycan structures after processing.
29
 For instance, IgG glycosylation at 
Asn297 is largely of the complex, biantennary type with varying amounts of core-fucose, 
galactose, and sialic acid depending on expression host and culture conditions.
30–32
 In addition, 
glycoproteins with multiple glycosylation sites often have distinct types of glycosylation at their 
different sites, indicating these differences are not due to simple compartmentalization of 
glycosidases and glycosyltransferases in the Golgi apparatus. An example of this is glycosylation 
of two sites on IgD, where it has been reported that the Asn445 glycosylation site is about 40% 
fucosylated while the Asn496 site is not fucosylated.
33
 Such specific glycan repertoires could be 
due to local protein structure or dynamics, accessory protein interactions, or a variety of other 
factors.  
 The strategy that was utilized to produce IgG2 Fc with and without core-linked 




ability to add core-linked fucose to produce high mannose IgG2 Fc, and then use in vitro 
enzymatic synthesis to convert the initial high mannose glycoform into homogeneous high 
mannose, hybrid and core-linked fucosylated hybrid (Fuc(+) hybrid) IgG2 Fc. This allowed the 
production of hybrid and Fuc(+)-hybrid glycoforms that differ only in the presence or absence of 
core-linked fucose for comparative studies.  During this process, we developed methods to 
produce the FUT8 enzyme in E. coli and utilized it to produce fucosylated glycoproteins.  This 
enabled studies of the effects of core-fucosylation on IgG2 Fc stability and receptor binding by a 
comparison of the behavior of the homogeneous hybrid and Fuc(+) hybrid glycoforms.  In 
addition, during the course of developing in vitro enzymatic methods to produce core-linked 
fucosylated IgG2 Fc, we noticed differences in the rates that FUT8 accepted free glycans versus 
protein-bound glycans.  Due to the relatively large-scale production of the homogeneous IgG2 Fc 
glycoforms described here we were able to further investigate these results with kinetic studies.  
The glycosylation site preferences of FUT8 for two different IgG2 Fc glycosylation site variants 
were studied and compared to the kinetics of fucose transfer to the free glycan.  These studies 
show that FUT8 has significant substrate specificity for different glycosylation sites on the same 
protein and these preferences appear to be caused by differences in glycosylation site 
accessibility. 
Results  
Production and characterization of IgG2 Fc glycosylation site variants 
The consensus sequence for human IgG2 heavy chain contains a single conserved N-
linked glycosylation site at Asn297 in the CH2 domain (Eu numbering).
1,7,8
 The human IgG2 




obtained from the mammalian gene collection
34
, contains an unusual polymorphism which 
results in an additional N-linked glycosylation site at Asn392 in the CH3 domain. Because of 
this, site-directed mutagenesis was utilized to convert the Asn392 residue from the cDNA 
template to a Lys392 residue to match the human IgG2 Fc consensus sequence.
1
 In addition, to 
better study the effect of different types of glycosylation sites on FUT8 kinetics, a second 
mutation was produced in which the Asn297 glycosylation site was removed by mutating it to a 
glutamine (Q297). The result of the subcloning and mutagenesis described here is three 
glycosylation variants of IgG2 Fc, one which matches the human IgG2 Fc consensus sequence 
with a single glycosylation site at Asn297 (N297, K392), one with a single glycosylation site at 
N392 (Q297, N392), and one derived from the original cDNA with two N-linked glycosylation 
sites (N297, N392), as illustrated in Figure 1. Hereafter the IgG2 Fc glycosylation variant which 
matches the consensus sequence (N297, K392) will be referred to as IgG2 Fc, and the other two 
glycosylation variants will be referred to as IgG2 Fc-(Q297, N392) and IgG2 Fc-(N297, N392) 



















Figure 1. IgG2 Fc glycosylation site variants utilized in this study: a) IgG2 Fc-(N297, N392); a 
naturally occurring but uncommon IgG2 glycosylation variant having an additional glycosylation 
site at residue 392 in addition to the well conserved Asn297 glycosylation site, b) IgG2 Fc-
(N297, K392); the widely accepted IgG2 Fc consensus sequence having a single conserved N-
glycosylation site at residue 297 in the CH2 domain and a lysine (K) residue at position 392, c) 
IgG2 Fc-(Q297, N392); an IgG2 Fc mutant designed to have an N-glycosylation site at residue 
392 in the CH3 domain but without the conserved N-glycosylation site at residue 297, for 





IgG2 Fc was expressed in an OCH1 deleted strain of SMD1168 Pichia pastoris produced 
previously in our laboratory.
35
 In this study, three 7-L BioFlo 415 fermentations were conducted 
to produce approximately 1 g of IgG2 Fc (Table I). The majority of this IgG2 Fc was 
diglycosylated. However, a minor fraction of hemiglycosylated Fc (one chain of the Fc dimer is 
glycosylated while the other chain is non-glycosylated) was present contaminating the 
diglycosylated Fc due to incomplete N-glycosylation site occupancy (Appendix: Figure A1 lane 
2 and Figure A2 panel A).
36,37
 The diglycosylated IgG2 Fc was separated from the 
hemiglycosylated Fc using hydrophobic interaction chromatography (HIC). After HIC, 395 mg 
of the purified diglycosylated IgG2 Fc was produced consisting of glycoforms containing mainly 
high mannose glycans with a small fraction of mannose phosphorylated glycans 
38
 present as 
shown in Figure A2 (panel B) of the appendix. We were able, however, to remove the mannose 
phosphorylated fractions by using weak cation exchange (WCX) chromatography to produce 185 
mg of purely high mannose IgG2 Fc containing mainly Man8GlcNAc2 and Man9GlcNAc2 high 
mannose glycoforms (Appendix: Figure A2, panel E). Presumably mannose phosphorylation 
adds additional negative charges to the glycoprotein (IgG2 Fc) and results in the reduction of the 
overall positive charge of the protein. Therefore, the phosphorylated fractions elute earlier from 
the WCX column than the non-phosphorylated fractions, which are more positively charged. 
Moreover, removal of the phosphorylation heterogeneity in this way allows subsequent complete 
digestion of the initial high mannose glycoforms to a homogeneous Man5 glycoform which can 
then be used as a starting material in the synthesis of hybrid and Fuc(+) hybrid glycoforms. 
Production of soluble mammalian α1,6-fucosyltransferase (FUT8) in E. coli 
FUT8, as a mammalian enzyme having four disulfide bonds, presents a potential problem 




number of disulfide bonds in FUT8, we decided to use an E. coli strain capable of forming 
disulfide bonds in the cytoplasm during protein expression. Recently, an E. coli protein 
expression strain named SHuffle has been engineered.
39
 This strain has diminished cytoplasmic 
reductive pathways and contains a cytoplasmic DsbC (an oxido-reductase chaperon) to facilitate 
the formation of correctly-folded, disulfide-bonded heterologous proteins with a high yield in the 
bacterial cytoplasm. An IPTG inducible plasmid construct was produced here to express the 
soluble domain of FUT8 in this bacterial strain. Transforming this strain directly with the FUT8 
expression construct resulted in an undetectable level of FUT8 expression (Appendix: Figure A3 
lane 6). However, transforming the FUT8-tranformed SHuffle T7 Express with the supplemental 
tRNA plasmid pRARE2 enabled expression of the recombinant FUT8 enzyme (Appendix: 
Figure A3 lane 9). The specific activity of FUT8 after purification was measured and found to be 
0.12 µmole/min/mg. The total FUT8 activity obtained from one liter bacterial expression was 
0.21 U (µmol/min).  
In vitro enzymatic synthesis of IgG2 Fc glycoforms 
Starting with high mannose IgG2 Fc obtained from yeast expression as a starting 
material, homogeneous Man5, hybrid, and Fuc(+) hybrid glycoforms were synthesized as 
















Figure 2. Enzymatic synthesis of homogeneous IgG2 Fc glycoforms and GDP-fucose. A) In 
vitro enzymatic synthesis of Man5, hybrid and Fuc(+) hybrid IgG2 Fc glycoforms using high 
mannose IgG2 Fc as a starting material. BT3990: bacterial α1,2- mannosidase; GnT-I: N-
Acetylglucosaminyltransferase I; FUT8: mammalian α1,6-fucosyltransferase. B) Reaction 
catalyzed by L-fucokinase/guanosine 5'-diphosphate-L-fucose pyrophosphorylase (FKP) for the 






The quantities and the yield of the different IgG2 Fc glycoforms produced in this study 
are summarized in Table I. First, 185 mg of high mannose IgG2 Fc (Figure 3A, also see 
Appendix Figure A4 lane 1) was digested with bacterial α1,2-mannosidase BT3990 (Zhu et al. 
2010; Cuskin et al. 2015; Okbazghi et al. 2016). Isolation of the product using protein G affinity 
chromatography resulted in 162 mg of Man5 IgG2 Fc which corresponds to 89% yield (Figure 
3B, also see Appendix Figure A4 lane 2). Next, treatment of 140 mg of Man5 IgG2 Fc with 
GnT-I (produced in house as described previously
42
) in the presence of UDP-GlcNAc resulted in 
formation of the hybrid glycoform. After protein G affinity chromatography, 130 mg of hybrid 
IgG2 Fc was obtained in 92% isolated yield (Figure 3C, also see Appendix Figure A4 lane 3). 
Finally, the Fuc(+) hybrid IgG2 Fc was produced from the hybrid IgG2 Fc glycoform using a 
FUT8-catalyzed reaction. The FUT8 reaction requires the presence of β1,2- linked GlcNAc on 
the α1,3-mannose arm of the acceptor substrate N-glycan
43
, which is provided in the hybrid 
glycoform. It also requires GDP-L-fucose as a donor substrate, which was made available by in 
situ formation of GDP-fucose from fucose, ATP, and GTP catalyzed by the enzyme FKP (Figure 
2B).
44
 FUT8 reaction progress was followed by intact protein mass spectrometry which showed 
that a full conversion of hybrid glycoform into the Fuc(+) hybrid glycoform over the course of 
two days (Figure 3D and 3E-H, also see Appendix Figure A4 lane 4). In this study, we converted 












Table I. IgG2 Fc glycoforms yields summary 









HIC purification 730 395 54 
WCX purification 395 205 52 
BT3990 reaction (synthesis of Man5 Fc) 185 162 89 
GnT-I reaction (synthesis of hybrid Fc) 140 130 92 










Figure 3. Intact protein mass spectra under reducing conditions for IgG2 Fc glycoforms, and 
time course for in vitro enzymatic synthesis of Fuc(+) hybrid IgG2 Fc. A) Heterogeneous high 
mannose IgG2 Fc glycoform obtained directly from Pichia pastoris after purification by Protein 
G, HIC and WCX chromatography, B) Man5 IgG2 Fc, C) hybrid IgG2 Fc, D) Fuc(+) hybrid 
IgG2 Fc. E-H: Time course for the enzymatic synthesis of the Fuc(+) hybrid IgG2 Fc glycoform 





Binding studies using biolayer interferometry (BLI) 
Biolayer interferometry (BLI) was used to measure the kinetics and strength of IgG2 Fc/ 
FcγRs interaction. For robust immobilization of the receptors, site-specific biotinylation of 
FcγRIIIa-V158, FcγRIIa-H131, and FcγRIIa-R131 at their C-termini was performed using 
sortase-mediated ligation.
45
 This biotinylation enabled site-specific immobilization of these 
receptors on streptavidin biosensors (Appendix: Figure A5). 
Although IgG2 is known to have the weakest binding for FcγRIIIa-V158 among all 
human IgG subclasses 
46
, our IgG2 Fc binding studies (Figure 4 and Table II) showed that hybrid 
IgG2 Fc binds detectibly, although weakly to FcγRIIIa-V158 (KD = 188 µM). Addition of core 
fucose to IgG2 Fc clearly reduced the binding to this receptor since the binding of Fuc(+) hybrid 
IgG2 Fc at 70 µM gave a weaker signal compared to the binding of hybrid IgG2 Fc at the same 
concentration. The concentration of Fuc(+) hybrid IgG2 Fc was raised to a higher level in an 
attempt to obtain stronger binding signals to calculate the binding constants. Unfortunately, the 
higher protein concentration resulted in massive distortion of the binding sensorgram (Appendix: 
Figure A6). Therefore, to get rough numbers for the binding of Fuc(+) IgG2 Fc to FcγRIIIa-
V158, we calculated these numbers based on a single concentration (70 µM) repeated in 
triplicate as shown in Figure A7 of the appendix. The KD calculated in this way was 2420 µM 
which is about 13-fold higher than the KD of binding the hybrid glycoform to FcγRIIIa-V158. On 
the other hand, the binding of the hybrid IgG2 Fc and Fuc(+) hybrid IgG2 Fc to FcγRIIa-H131 
variant was similar (KD= 2.1 µM). Finally, the effect of core fucosylation was also tested on the 
binding of IgG2 to FcγRIIa-R131 variant. The results showed similar binding constants for the 




general reduction (~ 8-fold) in IgG2 Fc binding affinity to this receptor variant of FcγRIIa 
compared to the H131 variant.  
 
 
Figure 4. Biolayer interferometry (BLI) analyses showing the sensorgrams for IgG2 Fc 
glycoforms binding to Fcγ receptors. A) binding of hybrid IgG2 Fc to immobilized FcγRIIIa-
V158, B) binding of Fuc(+) hybrid IgG2 Fc to immobilized FcγRIIIa-V158, C) binding of 
hybrid IgG2 Fc to immobilized FcγRIIa-H131, D) binding of Fuc(+) hybrid IgG2 Fc to 
immobilized FcγRIIa-H131, E) binding of hybrid IgG2 Fc to immobilized FcγRIIa-R131, F) 
binding of Fuc(+) hybrid IgG2 Fc to immobilized FcγRIIa-R131. Binding curves in A) 
correspond to hybrid IgG2 Fc concentrations of 70, 52.5, 35, and 17.5 µM from top to bottom. 
The binding curve in B) corresponds to a Fuc(+) hybrid IgG2 Fc concentration of 70 µM. 
Binding curves in C) and D) correspond to IgG2 Fc concentrations of 7.6, 3.8, 1.9, 0.9 µM from 
top to bottom. Binding curves in E) and F) correspond to IgG2 Fc concentrations of 9, 4.5, 2.2, 






















hybrid/FcγRIIIa-V158                                   8.01 ± 2.51 1.41 ± 0.05 188 ± 62 
Fuc(+)hybrid/FcγRIIIa-V158
a
  3.55 ± 2.94 8.58 ± 1.32 
 
2420 ± 2030 
hybrid/FcγRIIa-H131                                    817 ± 42 1.70 ± 0.14 2.08 ± 0.17 
Fuc(+) hybrid/FcγRIIa-H131                        821 ± 113 1.71 ± 0.13 2.12 ± 0.36 
hybrid/FcγRIIa-R131                                    174 ± 30 3.25 ± 0.3 18.6 ± 3.6 
Fuc(+) hybrid/FcγRIIa-R131                        189 ± 37 3.29 ± 0.06 17.4 ± 3.4 
 





Biophysical characterization and studies of IgG2 Fc glycoforms 
The stability and the structure of the CH2 domain of IgG isotype has been shown to be 
affected by the Asn297 glycan attached to this domain making it an important determinant of the 
overall Fc and antibody stability.
9,47
 The following biophysical techniques were used to probe the 
effect of core fucose on the stability of IgG2 Fc: size exclusion chromatography (SEC), circular 
dichroism (CD), differential scanning fluorimetry (DSF), and differential scanning calorimetry 
(DSC). 
Size exclusion chromatography (SEC) was used to measure any possible difference in the 
hydrodynamic radius between the fucosylated and non-fucosylated IgG2 Fc glycoforms as well 
as to check for the presence of any high molecular weight (HMW) species. The SEC 
chromatograms (Figure 5A) showed no sign of HMW species for both glycoforms. Also, there 
was no significant difference between the retention times of the hybrid (12.81 ± 0.02 min) and 
the Fuc(+) hybrid (12.80 ± 0.01 min) IgG2 Fc glycoforms suggesting no dramatic change in the 





Figure 5. Biophysical analyses of IgG2 Fc glycoforms. A) Size exclusion chromatography 
(SEC) chromatograms of the hybrid and Fuc(+) hybrid IgG2 Fc glycoforms analyzed under 




containing 0.4 M NaClO4. The mobile phase flow rate was 0.25 ml/min. Retention times were 
12.807 ± 0.018 min and 12.804 ± 0.009 min for the hybrid and Fuc(+) hybrid IgG2 Fc 
glycoforms, respectively. Also, the chromatograms indicate that both of these glycoforms are 
monomeric with no sign of high-molecular weight (HMW) species. B) Circular dichroism (CD) 
characterization of hybrid and Fuc(+) hybrid IgG2 Fc glycoforms. Both IgG2 Fc glycoforms 
exhibit similar CD spectra recorded in the far UV range (200–280 nm) at 10 °C in PBS (50 mM 
sodium phosphate, 150 mM NaCl, pH 7.4). C) CD-melt results recorded at 218 nm for hybrid 
and Fuc(+) hybrid IgG2 Fcs  in PBS using a 10-90 °C temperature range. The results show a 
high similarity in the CD-melt profiles of both glycoforms and also no significant differences in 
their thermal unfolding temperatures (Tonset and Tm, onset and midpoint of transition, 
respectively). Each sample was run in triplicate and buffer subtracted during data analysis. D) 
Differential scanning fluorimetry analyses using SYPRO Orange fluorescent dye for probing of 
the conformational differences between hybrid and Fuc(+) hybrid IgG2 Fcs. The Dye was diluted 
to 1X concertation and the samples buffer was PBS. The results show a typical mAb DSF profile 
for both glycoforms and similar transition temperatures (Tonset and Th, onset and midpoint of 
transition respectively). Each sample was run in triplicate and buffer subtracted.  E) and F) 
Differential scanning calorimetry thermograms of different IgG2Fc glycoforms. E) 
Deconvoluted thermograms of hybrid and Fuc(+) hybrid IgG2 Fcs. F) Deconvoluted 
thermograms of deglycosylated, EndoH-digested (GlcNAc-IgG2 Fc), and Man5 IgG2 Fcs. In 
each thermogram, the first transition represents the unfolding of the CH2 domain of the Fc while 
the second transition represents the unfolding of the CH3 domain. Each sample was run in 





The secondary structure of the hybrid and the Fuc(+) hybrid IgG2 Fc were examined by 
circular dichroism (CD). Both of these glycoforms showed the typical CD-spectrum of 
immunoglobulin G (Figure 5B) in which the beta sheet constitute the majority of its secondary 
structure giving rise to an ellipticity minimum around 218 nm.
48
 The spectra are also shown to be 
almost superimposable with no significant difference between them. A CD-melt was also 
conducted to detect changes in the protein secondary structure.
48,49
 In this analysis, the unfolding 
of the protein structure was followed up by recording the change in the protein ellipticity at 218 
nm as a function of temperature (Figure 5C). Data analysis showed no significant differences in 
Tonset (the starting temperature of the transition) and Tm (the midpoint of the transition) between 
the hybrid (Tonset= 62.1 ± 1.3 °C, Tm= 71.8 ± 0.6 °C) and the Fuc(+) hybrid (Tonset = 64.3 ± 0.9 
°C, Tm = 72.2 ± 0.9 °C) IgG2 Fc glycoforms. 
Fluorescence thermal shift analysis also known as differential scanning fluorimetry 
(DSF)
50
 was also used in this study to probe the effect of core fucosylation on IgG2 Fc 
conformational stability. In this experiment, SYPRO Orange was used as an extrinsic 
fluorophore. The DSF profiles of hybrid and Fuc(+) hybrid IgG2 Fc are shown in Figure 5D. 
Both glycoforms show a DSF profile which strongly resembles a typical DSF profile of a full 
length antibody.
51
 A typical antibody DSF profile shows a sharp sigmoid-like increase followed 
by a decrease in the fluorophore florescence intensity as the temperature increases. The initial 
increase in SYPRO Orange fluorescence intensity is due to the exposure of this dye to the apolar 
environment of the protein as it unfolds, while the later decrease in the intensity is at least 
partially due to florescence quenching by the intrinsic effect of temperature.
50
 Th of each 
glycoform, which is the midpoint of the first fluorescence transition in the corresponding DSF 




CH2 domain of mAb, since it is the least thermally stable domain.
50
 Data analysis showed no 
significant differences in Tonset (the starting temperature of the transition) and Th (the temperature 
of hydrophobic exposure) between the hybrid (Tonset= 60.9 ± 0.3 °C, Th= 66.1 ± 0.6 °C) and the 
Fuc(+) hybrid (Tonset = 60.6 ± 0.19 °C, Th = 66.1 ± 0.0 °C) IgG2 Fc glycoforms. 
The DSC thermograms of the different IgG2 Fc glycoforms are presented in Figure 5 
(panels E and F) while the melting temperatures are shown in Table III. In general, IgG2 Fc 
showed two endothermal transitions similar to the DSC thermogram of IgG1 Fc.
9
 This and 
previous results
47
 indicate that the first transition that occurs at a lower temperature (Tm1) 
represents the unfolding of the CH2 domain while the second transition which occurs at a higher 
temperature (Tm2) represents the unfolding of the CH3 domain of IgG2 Fc. In the first set of 
glycoforms (Figure 5E), we wished to test any possible effect of core fucose on the thermal 
stability of the CH2 domain using this biophysical technique. To this end, we used the 
homogeneous non-fucosylated and the Fuc(+) IgG2 Fc glycoforms generated in this study. Tm1 
was statistically identical for the hybrid and Fuc(+) hybrid IgG2 Fc glycoforms (68.4±0.1 °C and 
68.5±0.1 °C, respectively). The Tm2 transitions for hybrid and Fuc(+) hybrid IgG2 Fc 
glycoforms were also identical (76.5±0.1 °C each). In the second set of glycoforms (Man5 IgG2 
Fc, GlcNAc-IgG2 Fc, and deglycosylated IgG2 Fc), produced as described in the appendix, Tm1 
showed a progressive decrease in its value as the size of the Asn297 glycan becomes smaller 
while Tm2 did not change dramatically (Figure 5F). Interestingly, Tm1 of the Man5, hybrid, and 
Fuc(+) hybrid IgG2 Fc glycoforms were nearly the same (68.3±0.1, 68.4±0.1 and 68.5±0.1, 
respectively). This experiment also shows that Tm1 of Asn297 glycosylated forms of IgG2 Fc 




more than 4 °C. This difference reflects the importance of the glycosylation of Asn297 for the 
stabilization of the IgG2 Fc CH2 domain, as has been shown in previous studies.
9,47
 
Table III. Melting temperatures of CH2 domain (Tm1) and CH3 domain (Tm2) of different IgG2 
Fc glycoforms obtained by DSC 
               GlcNAcMan5F      GlcNAcMan5           Man5               GlcNAc-Fc      Deglycosylated-Fc 
Tm1
a
 (°C)    68.5±0.1                68.4±0.1               68.3±0.1               65.5±0.0              64.1±0.0 
Tm2
a
 (°C)    76.5±0.1                76.5±0.1               76.3±0.2               75.7±0.0              75.6±0.0        
 
aMelting temperatures were obtained by fitting the corresponding thermogram shown in Figure 5 to a non-2- state model with two transitions 
 
Mammalian α1,6-fucosyltransferase (FUT8) kinetics studies 
To get a better understanding of the amounts of bacterially produced FUT8 that would be 
necessary for large scale production of the Fuc(+) hybrid glycoform, kinetic studies of the FUT8 
enzyme were conducted using free and protein-bound hybrid glycan. During the course of these 
experiments, it was recognized that there was a significant difference between the rates of fucose 
transfer for free vs. protein-bound glycan. This was explored in more detail in an additional set 
of experiments by studying the rates of FUT8 action at two different protein glycosylation 
positions, the IgG2 Fc Asn297 and Asn392 glycosylation sites (Figure 1).  
FUT8 activity was measured using a continuous coupled spectrophotometric assay which 
requires no substrate labeling.
52
 Initial kinetic studies of the amount and purity of the bacterially 
produced FUT8 were conducted with free hybrid glycan. It was found that 0.21 units (µmol/min) 
of FUT8 with a specific activity of 0.12 µmole/min/mg were obtained from 1 L of bacterial 
culture. The KM of the bacterially produced mouse FUT8 for the hybrid glycan acceptor substrate 
was determined to be 17.0 µM, while the KM of this enzyme for the GDP-fucose donor substrate 





Figure 6. FUT8 kinetics analyses. A) FUT8 reaction progress using 80 µM of free (▲) and 
Asn297-bound N-glycans (●). The initial velocities for each substrate were calculated based on 
the drop in NADH concentration during the linear phase of the reaction using the pyruvate 
kinase/lactate dehydrogenase continuous coupled assay. B and C) Michaelis-Menten plots of 
FUT8 using free N-glycan (B) or Asn297-bound N-glycan (C) as an acceptor substrate for the 
calculation of apparent KM and Vmax. Each curve was constructed using initial velocities of varied 




were used while for the Asn297-bound N-glycan (●); 40, 60, 80, 100, 120, 140,190, and 300 µM 
were used. Data points are shown as the average of triplicate values. D) Lineweaver-Burk plot 
constructed using data from plots B and C, showing the difference in FUT8 kinetics between the 
free and the Asn297-bound N-glycan. E and F) Michaelis-Menten (E) and Lineweaver-Burk (F) 
plots of FUT8 using varied concentrations (10, 15, 20, 25, 30, 50, 80, 120, 360 µM) of the donor 
substrate (GDP-fucose) but fixed concentration (80 µM) of the free N-glycan as an acceptor 
substrate. 
Table IV. Kinetic parameters for mouse α1,6-fucosyltransferase FUT8 
Parameter                             Value
a
 (standard error) 
KM (free glycan) (µM)                               17.0 (1.0) 
Vmax (free glycan) (µmol/min/mg)                               0.12 (0.002) 
KM (Asn297-bound glycan) (µM)                               167.8 (10.0) 
Vmax (Asn297-bound glycan) (µmol/min/mg)                               0.12 (0.003) 
KM (GDP-fucose) (µM)                               18.2 
 
aValues were calculated using GraphPad Prism 7 software utilizing the data shown in Figure 6 
 
 The simplicity of the pyruvate kinase/lactate dehydrogenase coupled FUT8 assay gave us 
the opportunity to compare the acceptor substrate kinetics of a free hybrid glycan with a protein-
bound hybrid glycan. This was accomplished by conducting the FUT8 activity assay in the 
presence of varying concentrations of the Asn297 hybrid glycoform of IgG2 Fc (Figures 6). It 
was apparent immediately from initial rate studies that the free hybrid glycan is converted to the 
Fuc(+) hybrid glycan at a much higher rate than the IgG2 Fc Asn297 hybrid glycan under same 
conditions. Determination of kinetic parameters for the IgG2 Fc Asn297 hybrid glycan resulted 
in an interesting result. The KM of mouse FUT8 for the protein bound acceptor substrate was 




In addition, the Vmax of the free hybrid glycan and the protein-bound Asn297 hybrid glycan were 
essentially identical, 0.12 ± 0.002 µmol/min/mg and 0.12 ± 0.003 µmol/min/mg, respectively. 
This can also be seen in the Lineweaver-Burk plot in Figure 6D. 
The kinetics of the FUT8 reaction at a second protein glycosylation site was studied to 
determine if FUT8 differs in its ability to transfer fucose at different protein glycosylation sites. 
This was accomplished by producing a glycosylation site variant of IgG2 Fc with the Asn297 
site mutated to glutamine, and the consensus Lys392 residue converted to an asparagine to create 
a new N-linked glycosylation site as described in the appendix. This IgG2 Fc-(Q297, N392) 
variant has a single N-linked glycosylation site at Asn392 (Figure 1). Though the N392 
glycosylation site is not part of the IgG2 Fc consensus sequence, it is a naturally occurring 
polymorphism which is present in the initial human IgG2 heavy chain cDNA obtained from the 
mammalian gene collection
34
 and used for subcloning in this study. In addition, the human IgG3 
subclass heavy chain does have an asparagine at residue 392. Our laboratory and others 
27
 have 
shown that this site is glycosylated to some extent in human IgG3, and that the N-linked 
glycoforms present at this site are distinct from those found at the Asn297 glycosylation site 
(unpublished results). To study FUT8 reaction kinetics with the IgG2 Fc-(Q297, N392) 
glycosylation site variant, it was first necessary to synthesize the hybrid glycoform of IgG2 Fc-
(Q297, N392). This was accomplished using the same strategy that was utilized to produce the 
Asn297 hybrid glycoform of IgG2 Fc described previously, only using high mannose IgG2 Fc-
(Q297, N392) as a starting material. During the course of the synthesis of hybrid IgG2 Fc-(Q297, 
N392) glycoform, it became apparent that the Asn392 glycosylation site is not as good of a 
substrate when compared to the Asn297 site for glycosidase and glycosyltransferase enzymes. 




glycoforms of the Asn297 and Asn392 glycosylation sites on IgG2 Fc. The Man5 IgG2 Fc-
(Q297, N392) substrate is converted to the hybrid glycoform at a much slower rate than the 
Asn297 site of Man5 IgG2 Fc. Calculations based on mass spectra peak intensities and initial 
rate calculations showed that the GnT-I catalyzed reaction using Asn392 glycan as a substrate is 
slower than the enzyme reaction using Asn297 glycan as a substrate by a factor of 4. Once the 
hybrid glycoform of IgG2 Fc-(Q297, N392) was produced, it was incubated with FUT8 and 
GDP-fucose to determine the rate of fucose transfer to the Asn392 glycosylation site. No fucose 
transfer was detected for the Asn392 glycosylation site even though the Asn297 site was fully 
fucosylated in approximately 60 h under the same reaction conditions (Figure 7B). Based on 
these results, we have concluded that the Asn392 glycosylation site is not accepted as a substrate 






Figure 7. Effect of glycosylation site on glycosyltransferases reactions. A) GnT-I catalyzed 
reaction progress for the synthesis of the hybrid glycoform from Man5 glycoforms. The reaction 
was carried out in 20 mM HEPES pH 7.5 buffer containing 150 mM NaCl, GnT-I (25 µg/ml), 
UDP-GlcNAc (2 mM), MnCl2 (20 mM) and  20 µM of Man5 glycoform of either the wild type 
IgG2 Fc which contains only the Asn297 glycosylation site (■) or IgG2 Fc-(Q297, N392) which 
contains only the N392 glycosylation site (●). The reaction was followed up by Q-TOF LC/MS 
analysis of intact protein and the peak intensities were used to calculate the percentage of 
conversion of the Man5 glycoform into the hybrid glycoform. B) FUT8 catalyzed reaction 
progress for the addition of core fucose. The reaction was carried out in 50 mM Tris HCl pH 7.5 
buffer containing FUT8 (0.35 µU/ml), GDP-fucose (150 µM), and 20 µM of the hybrid 
glycoform of either the wild type IgG2 Fc (■) or IgG2 Fc-(Q297, N392) (●). The reaction was 
followed by Q-TOF LC/MS analysis of intact protein and the peak intensities were used to 





 Synthesis of homogeneous glycoproteins can facilitate studies of protein glycosylation by 
providing access to material to conduct experiments that is not available from natural sources.  
Natural glycoprotein microheterogeneity presents a significant obstacle to the analysis of 
glycoprotein receptor interactions, stability, and kinetic studies. As part of a larger project to 
produce homogeneous glycoproteins for glycobiology studies, human IgG2 Fc was produced as 
homogeneous Man5, hybrid, and Fuc(+) hybrid glycoforms in this work in a relatively large 
laboratory-scale using a combination of glycosylation-deficient host, purification, and enzymatic 
synthesis as shown in Table I.  These glycoforms were then used to study the effects of changes 
in glycosylation on IgG2 Fc stability, receptor binding, and the kinetics of glycosyltransferase 
reactions on IgG2 Fc glycosylation variants. IgG2 Fc was first produced in bulk in a BioFlo 415 
fermentor using an OCH1 deleted strain of SMD1168 Pichia pastoris.
53,54
 Approximately 1 g of 
high mannose IgG2 Fc was isolated from growth media using protein G chromatography. The 
protein G purified IgG2 Fc was then purified further using HIC and WCX chromatography. 
Though this results in a large loss of material, the purified high mannose IgG2 Fc obtained after 
chromatography is diglycosylated and consisting mainly of Man8GlcNAc2 and Man9GlcNAc2 
glycoforms that can be completely digested by α-1,2-mannosidases. Once the diglycosylated 
high mannose IgG2 Fc was produced, enzymatic conversion to homogeneous Man5 and hybrid 
glycoforms was conducted successfully as described in the methods section of this chapter. 
 For the production of the Fuc(+) glycoform and kinetic studies of fucose transfer to IgG2 
Fc, a novel method was developed to produce mouse FUT8 by cloning and expressing it in the 
cytoplasm of E. coli in a soluble and active form. Previously, FUT8 has been obtained from 






addition, recombinant expression of human FUT8 has been carried out in insect cells, and this 
recombinant FUT8 has been utilized for characterization of the FUT8 reaction mechanism, 
substrate specificity, and determination of FUT8 crystal structure.
22,57
 Though FUT8 can be 
obtained from all of the previously mentioned sources, we decided to explore the possibility of 
producing FUT8 in E. coli to take advantage of the ease and speed of bacterial protein 
expression. Using a modified E. coli strain, 1.8 mg of FUT8 with a total activity of 0.21 units 
(µmol/min) was produced from a one-liter shake flask expression. This amount of enzyme 
activity was sufficient to produce all of the fucosylated proteins and to do all the required 
characterization and the kinetic experiments described in this study.  Initial kinetic studies of the 
bacterially produced mouse FUT8 enzyme demonstrated that it had similar properties to the 
insect cell produced human FUT8 described by Ihara et al.
22
  The acceptor substrate KM of the 
bacterially produced mouse FUT8 from this study is 17.0 µM, which is close to the 12.9 µM 
acceptor substrate KM determined for insect cell-produced human FUT8 reported by Ihara et al.
22
 
At the same time, the donor substrate KM of mouse FUT8 is 18.2 µM, which is nearly identical to 
the 19.3 µM donor substrate KM Ihara et al. reported for human FUT8 
22
, despite the difference in 
FUT8 assay formats used in these studies. 
 Several studies have demonstrated that the N-linked glycan at Asn297 stabilizes the CH2 
domain of antibody IgG Fc regions. Removal or truncation of this glycan affects conformational 
stability, aggregation rates and biological activity.
9,45,58–61
 Given that little is known about hybrid 
glycoforms in IgG2, we conducted a series of biophysical experiments to determine if core-
linked fucosylation affects its conformational stability. Previously, Sondermann et al. 
62
 
demonstrated that the addition of sialic acid (a terminal glycan heterogeneity) to the Asn297 




the thermal stability of this domain as measured by circular dichroism. However, in this study 
overall results from biophysical experiments to probe the effect of core fucosylation on the 
structure of IgG2 Fc confirm the similarity in the Fc structure upon core fucosylation and suggest 
that core fucose does not make a significant contact with the protein backbone. These results are 
also consistent with previous results, where stable isotope-assisted NMR analyses confirmed the 




  Of the human IgG subclasses, IgG2 has the weakest interaction with most Fcγ receptors, 
with the only exception being FcγRIIa where IgG2 has moderate affinity.
46
 Because of this, IgG2 
is a weak initiator of cellular immune responses except for those linked to cells expressing 
FcγRIIa. These relatively low effector functions of IgG2 have been utilized by the 
pharmaceutical industry to make mAb when the effector functions are not required for the 
antibody mechanism of action. Even so, IgG2 has measurable affinity to other Fc receptors and 
may contribute to cellular immune responses initiated by those other Fc receptors by acting alone 
or with other IgG subclasses. Binding of IgG subclass to these receptors is highly affected by the 
microheterogeneity of the Asn297 glycan, especially the level of core fucosylation.
14
 To explore 
the effect of core fucosylation on the binding of IgG2 to Fcγ receptors, we conducted kinetic 
binding studies of the interactions of two Fc receptors (FcγRIIa and FcγRIIIa) with non-
fucosylated and core-linked fucosylated IgG2. Since IgG2 has generally weak affinity for 
FcγRIIIa, we chose to study the high affinity variant of this receptor, i.e. FcγRIIIa-V158. 
Meanwhile, in FcγRIIa binding studies, we chose both the high affinity (FcγRIIa-H1131) as well 
as the low affinity (FcγRIIa-R131) variants of this receptor. Biolayer interferometry studies of 




binding while at the same time it appears to reduce binding to FcγRIIIa-V158 by about 13-fold. 
Thus, the reduction in binding to FcγRIIIa-V158 upon complete core fucosylation of IgG2 Fc 
could add more advantages to this IgG subclass and improve its benign nature when designing 
mAb intended to have low effector functions for certain disease conditions.   
 The reduction in the binding of fucosylated IgG2 Fc to FcγRIIIa-V158 in this study is 
shown to be due to a reduction in the rate of the formation of the Fc/Fcγ receptor complex as 
well as an increase in the rate of dissociation of this complex. Previously, it was shown that the 
presence of core fucose on the Asn297 glycan of IgG1 interrupt glycan-glycan interactions that 
are present between non-fucosylated Asn297 glycan of IgG1 and Asn162 glycan of FcγRIIIa-
V158.
18,19
 Therefore, a similar interaction might also be happening between IgG2 Fc and 
FcγRIIIa-V158 glycans and could explain the results reported in this study. Noticeably, our 
binding studies showed that the ka of binding of IgG2 Fc to FcγRIIa-H131 is about 100-fold 
bigger than that for binding to FcγRIIIa-V158 while the kd values from these interactions were 
about the same. This means that the higher affinity of IgG2 subclass for FcγRIIa-H131 relative to 
FcγRIIIa-V158 is mainly due to an increase in the rate of the formation of the Fc/Fcγ receptor 
complex rather than the stability of this complex. Even though these receptors have a high degree 
of homology, the difference in some of the amino acid sequence, and hence different receptor 
conformation and different number of N-linked glycans, may result in different modes of 
interaction and may account for these differences in binding kinetics. Our binding studies with 
FcγRIIa-R131 variant also showed that the reduction in IgG2 Fc binding affinity to this receptor 
variant compared to FcγRIIa-H131 variant (~ 8-fold reduction) is due to a combination of 
reduction in the rate of formation of the complex and reduced stability of the complex. 




core fucose has been shown to reduce the binding of IgG1 to this receptor variant as reported in 
previous studies.
14
 This result also suggests that IgG2 has a different mode of interaction with 
FcγRIIa-R131 than IgG1.  
  The amount of hybrid IgG2 Fc produced in these studies and the use of a pyruvate 
kinase/lactate dehydrogenase coupled assay to monitor FUT8 activity enabled studies of FUT8 
fucose transfer kinetics with both free and protein-bound hybrid glycans. Initial kinetic studies 
comparing the rates of fucose transfer to free and IgG2 Fc Asn297-bound hybrid glycans 
indicated that transfer of fucose was much more rapid to the free hybrid glycan. This was further 
investigated by more detailed kinetic studies to determine the FUT8 KM and Vmax parameters for 
both free and protein-bound hybrid glycan acceptor substrates.  Interestingly, the free hybrid 
glycan had a KM of 17 µM and the IgG2 Fc Asn297-bound hybrid glycan had a KM of 168 µM, 
indicating that the free glycan is the preferred acceptor substrate for FUT8. Unlike the KM values, 
the Vmax values determined for the free and IgG2 Fc Asn297-bound hybrid glycans were 
essentially identical at 0.12 µmol/min/mg. A standard interpretation of the KM's from this 
experiment indicates that the apparent affinity of the FUT8 active site for free hybrid glycan is 
approximately 10-fold higher than its affinity for the IgG2 Fc Asn297-bound hybrid glycan.  In 
addition, the fact that the Vmax values determined for each substrate were identical indicates that 
the catalytic rate constants and by implication the transition states for these two substrates are 
very similar, regardless of differences in active site affinity for initial substrates. Recent crystal 
structures of IgG1 Fc glycoforms showing both open and closed conformations around the 
Asn297 glycan in the interface between CH2 domains, and NMR studies of IgG1 Fc by the Barb 
laboratory which demonstrate that the first GlcNAc residue of the Asn297 glycan experiences 
multiple chemical environments, both suggest another intriguing possibility.
64–66




explanation for these kinetic results would be that the IgG2 Fc Asn297-hybrid glycan is dynamic 
and can exist in two or more conformations where at least one conformation would be fully 
accessible to the FUT8 active site and another conformation or conformations would be 
completely inaccessible. This sort of a model would be consistent with the kinetic results if 10% 
of the IgG2 Fc Asn297-hybrid glycans were in a fully accessible conformation and 90% were 
completely inaccessible, and the glycans were able to exchange between these different states. 
Regardless of whether FUT8 simply has lower affinity for protein-bound hybrid glycans or the 
IgG2 Fc Asn297-hybrid glycan is dynamically moving between accessible and inaccessible 
states, the slower rates observed for fucose transfer to the IgG2 Fc Asn297-does appear to agree 
with what is known of the FUT8 mechanism.
22,57,67
 FUT8 requires significant access to N-linked 
glycans to catalyze fucose transfer because for substrate recognition it must bind to non-reducing 
end sugar residues and then transfer fucose to the reducing end GlcNAc residue attached to 
Asn297. To further investigate the steric requirements for FUT8 transfer of fucose to hybrid 
glycans, we decided to investigate a second IgG2 Fc glycosylation site. 
 Recent studies in our laboratory (unpublished results) and others 
27
 have shown that the 
IgG3 Asn392 glycosylation site is occupied and has distinctly different types of N-glycans 
attached to it when compared to the Asn297 glycosylation site. While the glycans of the IgG3 
N297 site are mainly complex biantennary glycans containing core-linked fucose, the glycans 
found on IgG3 Asn392 contain no core-linked fucose at all and also contain a large amount of 
bisecting GlcNAc.  Since the presence of bisecting GlcNAc blocks the enzymatic activity of 
FUT8
68
, one question about the differences between the types of glycosylation found on the 
IgG3 Asn297 and Asn392 sites is whether the addition of bisecting GlcNAc is blocking the 




on the Asn297 and Asn392 IgG3 sites indicated that we might expect to observe similar 
differences between the homologous Asn297 and Asn392 glycosylation sites on IgG2 Fc since 
IgG2 Fc is highly homologous to IgG3 Fc. A mutant was produced to eliminate the Asn297 
glycosylation site but retain the Asn392 glycosylation site of IgG2 Fc (IgG2 Fc-(Q297, N392)) 
so that both sites could be studied independently. Studies of the rates of glycosyltransfer for 
formation of the hybrid glycoform with GnT-I and for formation of the Fuc(+)-hybrid glycoform 
using FUT8 were conducted on both sites. The IgG2 Fc Asn392 glycosylation site appears to be 
significantly less accessible to glycosyltransferases than the Asn297 site. GnT-I transferred 
GlcNAc to the Asn297 site approximately 4 times faster than to the Asn392 glycosylation site, 
and FUT8 did not transfer fucose to the Asn392 site at all while the Asn297 site was completely 
fucosylated. This is in some ways surprising since the Asn297 glycans appear in crystal 
structures to be sterically hindered by their location between the two CH2 domains of the Fc 
dimer, while the N392 side chain appears to be directed towards solvent in models. These results 
indicate that the protein structure around the Asn392 site makes it less accessible for transfer of 
GlcNAc to the non-reducing end of the Man5 glycoform and completely inaccessible for transfer 
of fucose by FUT8. Also, if the IgG2 Fc results are indicative of what can be expected for IgG3, 
then the lack of fucose found on the human IgG3 Asn392 site is due to FUT8 not being able to 
accept the Asn392 site as a substrate rather than the presence of bisecting GlcNAc blocking 
FUT8 activity.   
 In conclusion, we were successful in performing an in vitro enzymatic synthesis for the 
addition of core fucose to the Asn297 of IgG2 Fc. Complete core fucosylation of IgG2 Fc using 
this synthesis resulted in a large reduction (~ 13-fold) in binding of this IgG subclass to 




no effector functions.  As part of this in vitro enzymatic synthesis, methods were developed to 
express mouse FUT8 in E. coli for rapid production of FUT8 for enzymatic synthesis and 
kinetics studies.  Biophysical studies comparing the stability of hybrid and Fuc(+)-hybrid IgG2 
Fc glycoforms were carried out, and it was found that the two glycoforms had nearly identical 
stability. The acceptor substrate specificity of FUT8 for a free hybrid glycan and two different 
IgG2 Fc hybrid glycosylation sites was determined. FUT8 accepted the free hybrid glycan with a 
10-fold lower KM than the IgG2 Fc Asn297-hybrid glycoform, but with equal Vmax indicating 
similar transition states for the free and protein-bound glycans. The IgG2 Fc Asn392-hybrid 
glycoform was not accepted by FUT8 as a substrate, indicating that this site is probably sterically 
hindered by the surrounding protein structure. Based on these kinetic results, the protein 
structure around hybrid glycans affect fucose transfer catalyzed by FUT8 by altering KM but not 
Vmax, and this observed substrate specificity could explain differences in the types of N-linked 
glycans found attached to different glycosylation sites on the same protein. 
Materials and methods 
Materials 
 Restriction endonucleases, endoglycosidase H, and SHuffle T7 Express E. coli were 
purchased from New England Biolabs (Ipswich, MA). Amicon Ultra-15 Centrifugal Filter Units 
were purchased from EMD Millipore (Billerica, MA). SYPRO Orange dye, and Top10F’ E. coli 
cells were obtained from Invitrogen Inc. (Carlsbad, CA). The bacterial α1,2-mannosidase, 
BT3990
40,41
, was produced in house. The biotinylated FcγRIIIa-V158 variant was produced in 
house by the procedure described by Okbazghi et al.
45
 The plasmid pRARE2 was isolated from 




purchased from ThemoScientific (Grand Island, NY). UDP-GlcNAc, Inorganic pyrophosphatase 
from baker's yeast (S. cerevisiae), NADH, Pyruvate Kinase/Lactic Dehydrogenase enzymes from 
rabbit muscle, ATP, GTP, and L-fucose were obtained from Sigma-Aldrich (St. Louis, MO). 
Production and characterization of IgG2 Fc 
 A description of the cloning and site-directed mutagenesis used to produce yeast 
expression strains for the IgG2 Fc glycosylation site variants shown in Figure 1 is provided in the 
appendix. IgG2 Fc variants were expressed in an OCH1 deleted strain of Pichia pastoris, using a 
BioFlo 415 fermenter (Eppendorf) on a 7-liter scale. The expression and purification of IgG2 Fc 
are described in more details in the appendix. Briefly, three 7-L fermentations were conducted to 
produce about 1g of the IgG2 Fc. A second purification step using hydrophobic interaction 
chromatography (HIC) was also carried out to separate hemiglycosylated Fc from the 
diglycosylated Fc.
37,60
 Weak cation exchange chromatography was also utilized to purify IgG2 
Fc further and get rid of the phosphorylated glycoforms.  
Production of soluble mammalian α1,6-fucosyltransferase (FUT8) in E. coli 
An expression plasmid (pFUT8) for the production of the catalytic domain of mouse 
FUT8 fused to a hexa histidine-tag was produced as described in the appendix. The pFUT8 
plasmid was then transformed into SHuffle T7 Express E. coli. The expression and purification 
of FUT8 are described in the appendix. After purification, the enzyme solution was dialyzed 
against 50 mM Tris HCl, pH 7.5 buffer and concentrated by Amicon ultra-15 centrifugal filter 
unit. Finally, the enzyme concentration was measured using Pierce BCA protein assay kit 





In vitro enzymatic synthesis of IgG2 Fc glycoforms 
The enzymatic synthesis scheme shown in Figure 2 was followed to make homogeneous 
IgG2 Fc glycoforms as described in the following sections: 
 Man5-IgG2 Fc 
High mannose IgG2 Fc produced by yeast expression and subsequent purification was 
converted into a homogeneous Man5GlcNAc2 (Man5) IgG2 Fc glycoform using a bacterial α1,2-
mannosidase (BT3990).
40,41,45
 Prior to BT3990 digestion, 185 mg of high mannose IgG2 Fc 
(Figure 3A) was dialyzed against the reaction buffer (20 mM MES buffer pH 6.6 containing 150 
mM NaCl and 5 mM CaCl2). Then, the reaction mixture (92.5 ml) containing IgG2 Fc (2 mg/ml) 
and BT3990 (100 µg/ml) was incubated at room temperature and the conversion was monitored 
by intact protein Q-TOF LC/MS and required two days for completion. Finally, the Man5 
glycoform was purified from the reaction mixture using the general protein G affinity 
chromatography procedure described in the appendix. 
 Hybrid-IgG2 Fc 
Man5 IgG2 Fc was converted into GlcNAcMan5GlcNAc2 (hybrid) IgG2 Fc using in-
house produced N-acetylglucosaminyltransferase I (GnT-I).
42
 Before the reaction, Man5 IgG2 Fc 
was dialyzed against 20 mM HEPES pH 7.5 buffer containing 150 mM NaCl. The reaction 
mixture (15.5 ml) containing 139.5 mg Man5 IgG2 Fc (9 mg/ml), GnT-I (117 µg/ml), UDP-
GlcNAc (2 mM), and MnCl2 (20 mM) was incubated at 28 °C. The reaction was monitored using 
intact protein Q-TOF LC/MS until completion (11 hours). The hybrid Fc was purified from the 






Core-linked fucosylated IgG2 Fc (Fuc(+) hybrid-IgG2 Fc) 
FUT8 produced as described above was utilized to convert the hybrid IgG2 Fc glycoform 
into the GlcNAcMan5GlcNAc2F (Fuc(+) hybrid) IgG2 Fc glycoform. The donor substrate, GDP-
L-fucose, required for FUT8 reaction was produced in situ from L-fucose, ATP, and GTP using 
the bifunctional enzyme L-fucokinase/guanosine 5'-diphosphate-L-fucose pyrophosphorylase 
(FKP) (Figure 2B). FKP was cloned and expressed as described previously by Wang et al.
44
 with 
minor modification as shown in the appendix. The FKP reaction was carried out in 50 mM Tris 
HCl pH 7.5 buffer containing ATP (5 mM), GTP (5 mM), L-fucose (5 mM ), MgCl2 (5 mM), 
and FKP (120 µg/ml) at room temperature. After 12 hours, the FKP reaction mixture was added 
to an equal volume (8 ml) of a solution containing 20 mg of hybrid IgG2 Fc (2.5 mg/ml Fc in 20 
mM Tris HCl buffer pH 7.5) and the conversion to Fuc(+) hybrid was initiated by adding 37.3 
µU of FUT8 and monitored by intact protein mass spectrometry. By the end of the reaction, the 
Fuc(+) hybrid Fc was purified from the reaction mixture using the general protein G affinity 
chromatography procedure described in appendix. 
Binding studies using biolayer interferometry (BLI) 
The interactions of the non-fucosylated and fucosylated IgG2 Fc glycoforms with Fcγ 
receptors FcγRIIa-H131, FcγRIIa-R131, and FcγRIIIa-V158 were studied using a BLItz
®
 
instrument (Pall ForteBio LLC). The soluble form of human FcγRIIIa-V158 receptor used in 
these binding studies was previously cloned and produced in our laboratory.
35,45
 The cloning, 
expression, and purification of the soluble form of human FcγRIIa-H131 and FcγRIIa-R131 
receptors are described in the appendix. In these binding experiments, streptavidin biosensors 
(Pall ForteBio LLC) were chosen for the immobilization of the receptors while the studied IgG2 




were used in each binding experiment and each binding experiment was repeated three times. 
The association rate constant and the dissociation rate constant (ka and kd, respectively) as well as 
the equilibrium dissociation constant (KD) at 25 °C were calculated by fitting the binding 
sensorgrams from these different concentrations using the global fit function of BLItz Pro 
software. More details on the binding experiments are provided in the appendix. 
Biophysical studies  
 Size exclusion chromatography (SEC) 
Size exclusion chromatography (SEC) analyses were conducted using a TSKgel Super 
SW3000 (4.6 mm ID x 30 cm, Tosoh Bioscience, King of Prussia, PA) column and Prominence 
HPLC system (Shimadzu, Kyoto, Japan). A 6-µl sample volume of 4.5 µM (about 0.24 mg/ml) 
of either hybrid or Fuc(+) hybrid IgG2 Fc glycoform in PBS (50 mM sodium phosphate, 150 
mM NaCl, pH 7.4) was injected into the column. The mobile phase used was 0.05 M NaH2PO4 
buffer pH 6.1 containing 0.4 M NaClO4. The flow rate was 0.25 ml/min and the UV detector was 
set at 214 nm. 
 Circular dichroism (CD) spectroscopy 
The far UV-CD spectra (from 280-200 nm) of the hybrid and the Fuc(+) hybrid IgG2 Fc 
in PBS were recorded at 10 °C using a Chirascan instrument (Applied Photophysics, Surrey, 
United Kingdom) equipped with a six position temperature-controlled sample holder. Samples 
were prepared by loading 200 µl of 3.8 µM (about 0.2 mg/ml) of each IgG2 Fc glycoform in 
PBS (50 mM sodium phosphate, 150 mM NaCl, pH 7.4) into 0.1 cm path length quartz cuvettes. 
The scanning speed was 2 nm/sec at 1.0 nm resolution. Each sample was run in triplicate and 




the molar ellipticity at 218 nm of each sample as a function of temperature. The temperature was 
raised from 10-90 °C at 2.5 °C intervals using a heating rate of 15 °C/h with the samples allowed 
to equilibrate for 5 min at each temperature. The CD-melt profile for each glycoform was 
obtained by plotting the molar ellipticity at 218 nm as a function of temperature.
49
 
 Differential scanning fluorimetry (DSF) 
DSF was performed using a MX3005P qPCR system (Agilent Technologies). The 
samples were prepared by adding sufficient SYPRO Orange dye to protein solutions (3.8 µM 
IgG2 Fc in PBS) to create a 1X- final SYPRO Orange concentration. 150 µl of each sample was 
loaded into a 96-well plate. The samples solution was excited at 492 nm, and the emission 
intensity at 610 nm was followed with a concomitant raise in the temperature from 25-100 °C at 
1°C/min ramping speed. Each sample was also run in triplicate and buffer subtracted.  Data 
analysis was performed using Origin software and DSF profiles were constructed by plotting 
SYPRO Orange fluorescence intensity as a function of temperature.
50,60,61
 
 Differential scanning calorimetry (DSC) 
DSC experiments were performed with a MicroCal VP-AutoDSC instrument (MicroCal, 
LLC, Northampton, MA). Data was collected from 15 to 90 °C at a scanning rate of 60 °C/h for 
Fc solutions of 1 mg/ml concentration in 20 mM sodium phosphate buffer pH 6.00. The sample 
volume was 400 µl and each sample was run in triplicate. Data analysis was performed using the 
DSC data analysis software supplied by Microcal (Origin 7). In this analysis, the protein sample 
thermogram was subtracted from the buffer thermogram, baseline fitted, and normalized by 
concentration to obtain the final thermogram. The resulting thermograms were then fit to a non-




second (Tm2) transitions which correspond to the heat capacity peak maximum of the first and 
second endotherms in the thermograms, respectively.
61
 
FUT8 (α1,6-fucosyltransferase) kinetics studies 
 FUT8 activity assay 
A continuous coupled spectrophotometric assay similar to one described previously for 
α1,3-fucosyltransferase
52
 was used to determine FUT8 catalytic activity. In this assay, the FUT8 
reaction progress was followed by measuring UDP production (produced when FUT8 transfers 
fucose from GDP-L-fucose to the acceptor substrate, Figure 2A) with a pyruvate kinase/ lactate 
dehydrogenase (PK/LDH) coupled system to monitor NADH disappearance at 340 nm. This 
assay was performed in 50 mM HEPES buffer pH 7.5 containing GDP-fucose (350 µM, 
prepared as described in the appendix), potassium chloride (50 mM), phosphoenolpyruvate (0.75 
mM), NADH (0.15 mM), free hybrid (GlcNAcMan5GlcNAc2) glycan (80 µM, prepared as 
descried in the appendix), 3 U pyruvate kinase (PK), and 4.2 U lactate dehydrogenase (LDH). 
The final volume was 150 µl and the reaction was started by the addition of FUT8 (4.5 µg) after 
letting the other components equilibrate for 5 min inside the cuvette at 37 °C. The decrease in 
NADH absorbance at 340 nm with time was followed using Evolution 260 Bio UV-visible 
spectrophotometer (ThermoScientific). The assay was done in triplicate and each time a blank 
(no GDP-fucose) was subtracted. 
 Determination of FUT8 kinetic parameters (KM and Vmax) 
For determination of FUT8 kinetic parameters (apparent KM and Vmax), the same assay 
conditions described above were used but with varied substrate concentrations. To determine 




40-300 µM. To determine FUT8 KM and Vmax of the free glycan (Asn297 released N-glycan), the 
concentration of this glycan was varied from 10-120 µM. In both cases, the concentration of the 
donor substrate (GDP-fucose) was fixed at 360 µM. Glycan concentration calculation was based 
on initial IgG2 Fc concentration, as determined by absorbance at 280 nm, in which the glycan 
concentration is twofold the Fc concentration (two glycans per Fc dimer). To determine FUT8 
KM and Vmax with respect to GDP-fucose, the concentration of this nucleotide sugar was varied 
from 10-360 µM while the concentration of the acceptor substrate (free glycan used in this case) 
was kept at 80 µM. In all cases, equal amounts of FUT8 (0.52 µU in a reaction volume of 150 
µl) were used to measure the kinetic parameters. Data analysis was performed using GraphPad 
Prism 7 software. The initial velocities at various concentrations were measured for each 







Statistical analysis was done using unpaired t test to compare the different parameters. All 
statistical analyses were performed using GraphPad software. A p-value of less than 0.05 was 
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FUT8-catalyzed functionalization of Asn297 glycan of IgG2 Fc for the design of 






  Antibody drug conjugates (ADCs) represent a rapidly growing class of pharmaceutical 
products and hold a considerable promise for the treatment of many diseases, especially cancer.
1
 
Antibody drug conjugates are hybrid molecules combining the tumor-targeting specificity and 
long circulating half-life of the monoclonal antibody (mAb) with the enhanced antitumor activity 
of toxic payload attached to them. The recent approval of Seattle Genetics’s brentuximab vedotin 
(in 2011) and Immunogen’s trastuzumab emtansine (in 2013) has sparked a tremendous interest 




 The first generation ADCs relied on the conventional conjugation chemistries through the 
epsilon-amino group of lysine and the thiol group of reduced disulfide bond cysteine. However, 
these early conjugation methods result in heterogeneous ADCs that are mixtures of molecules 
different in the number and sites of attachment of the drug on the mAb part of the ADC. For 
example, there are about 40 lysine residues per mAb and a stochastic drug conjugation using  
this amino acid in a mAb would generate more than million different species.
3
 This 
heterogeneity of the ADC prepared by conventional methods adds more complication to the 
development and regulatory approval of ADCs since the mAb part of these products may already 
have a certain level of heterogeneity to start with due to posttranslational modifications, such as 
the variation in the Asn297 glycosylation profile.
4
 Therefore, such products require more control 
of the production processes and extensive characterization to ensure an acceptable consistency 
across different production batches. 
The site of conjugation has also been shown to be critical for ADC stability and 
pharmacokinetics and a better control of the conjugation site could improve the overall ADC 
tolerability and widen the therapeutic index.
5,6




the advances in the fields of protein engineering and conjugation chemistry, the focus of the 
pharmaceutical industry and many other research groups has changed to produce ADCs through 
site-specific conjugation
2,7–11
 One of the leading technologies to make site-specific ADC is the 
so called THIOMAB technology.
5
 In this technology, an antibody was engineered to have extra 
cysteine residues at specific sites to be used in conjugating the payload through thiol reactive 
linkers instead of using the reduced disulfide bonds cysteines of the antibody for conjugation. 
This technology yielded nearly homogeneous conjugates with good safety profiles. The 
emergence of the THIOMAB technology has paved the way for many other approaches designed 
to make site-specific ADC with better control of the location of the cytotoxic drug, drug to 
antibody ratio (DAR), and homogeneity as critical parameters in determining the efficacy and 
safety profile of the resultant ADC. Some of these approaches relied on genetic engineering of 
the expression host to introduce an unnatural amino acid (UAA) containing a bioorthogonal 
handle at certain sites within the amino acid sequence of the mAb to enable site-specific 
conjugation.
12,13
 Other approaches utilized certain enzymes such as formylglycine generating 
enzyme (FGE)
14
 and sortase A (Srt A)
15
 that can recognize a specific amino acid sequence within 
the antibody peptide backbone to introduce a handle that enables site-specific attachment of 
payload using suitable conjugation chemistries. 
An interesting site for making site-specific ADC is the well-conserved Asn297 glycan 
located in the CH2 domain of the antibody (IgG).
11
 Conjugation through this glycan could 
minimize any potential reduction in the ADC affinity for the target ligand since it is relatively 
distant from the Fab region of the antibody. Also, located away from the FcRn binding site, the 
Asn297 glycan does not affect binding of the antibody to this receptor, which is an essential 






approaches have been developed to functionalize this glycan for site-specific conjugation. Some 
of these approaches relied on the use of chemical means to functionalize certain sugar units 
within this glycan such as periodate oxidation of the core fucose to introduce an aldehyde group 
for conjugation with hydrazide derivatives.
19
 Metabolic engineering was also used to introduce 
unnatural sugar units to the Asn297 glycan such as the 6-thiofucose, where this unnatural thio-
sugar could be used for conjugation using thiol-maleimide chemistry to produce ADCs.
20
 In vitro 
chemoenzymatic synthesis using glycosyltransferases to place unnatural sugar units containing a 
suitable handle on this glycan was also utilized.
11
 For example, an engineered 
galactosyltransferase (Y289L) was used to add GalNAc analogues, such as GalNAz or 2-keto-
Gal, to the Asn297 glycan for subsequent conjugation using bioorthogonal chemistry.
21–24
 
Conjugation through the Asn297 glycan can be a promising and a straightforward strategy to 
equip antibodies with a suitable payload without the need for antibody engineering. 
In this work we developed an efficient method for bioorthogonal functionalization of the 
Asn297 glycan using in vitro mammalian α1,6-fucosyltransferase (FUT8)-catalyzed 
chemoenzymatic synthesis to place the unnatural sugar 6-azido-L-fucose on this glycan. This 
method was utilized in making homogeneous conjugates using different types of linkers having 
different physicochemical properties combined with different bioorthogonal click chemistry. 







In vitro chemoenzymatic functionalization of Asn297 glycan for bioorthogonal click reactions 
 The core linked fucose (α1,6-fucose) position of the Asn297 glycan of IgG was targeted 
in this study as a site for adding a modified sugar (6-azido-L-fucose) to provide a bioorthogonal 
handle for site-specific conjugation to make ADCs. Due to the need for milligram quantities of a 
highly homogeneous afucosylated IgG2 Fc to perform this study, we used the yeast Pichia 
pastoris to express this Fc coupled with in vitro enzymatic synthesis as described in chapter 2. 
The addition of 6-azido-L-fucose was carried out via in vitro FUT8-catalyzed reaction shown in 
Figure 1A. FUT8 is a mammalian enzyme that catalyzes core fucosylation of N-glycans.
25,26
 
Initially, we tried to perform the addition of the modified sugar to the Asn297 glycan by 
following a one-pot strategy similar to the one-pot strategy that we followed in chapter 2 for the 
addition of the natural sugar fucose to the Asn297 glycan. During the one-pot strategy, the 
formation of the nucleotide sugar (GDP-azidofucose), required for FUT8 reaction, from the 
simple sugar (6-azido-L-fucose) is catalyzed in situ by FKP. FKP is a bifunctional enzyme where 
it catalyzes the formation of GDP-azidofucose from 6-azido-L-fucose in two steps as shown in 
Figure 1B.
27,28
 In the first step, it converts 6-azido-L-fucose into 6-azido-L-fucose-1-phosphate 
through its kinase activity while in the second step it converts 6-azido-L-fucose-1-phosphate into 





Figure 1. Site-specific functionalization and conjugation through Asn297 glycan of IgG2 Fc. A) 
FUT8-catalyzed functionalization of IgG2 Fc followed by conjugation of different linkers using 
biorthogonal click reactions. B) Reaction catalyzed by FKP for the synthesis of guanosine 5′-
diphospho-β-L-6-azido-fucose (GDP-azidofucose) from 6-azido-L-fucose. FUT8: mammalian 
α1,6-fucosyltransferase. FKP: L-fucokinase/guanosine 5'-diphosphate-L-fucose 
pyrophosphorylase. 
 
Although the one-pot strategy eventually results in complete functionalization of the 
IgG2 Fc (Appendix: Figure B1), the conversion was slow and required nine days compared to 
only two days conversion when the natural sugar fucose is used instead of the modified sugar 6-
azido-L-fucose (Figure 2A). The one-pot strategy involved three enzyme catalytic steps: two 




add the sugar to the glycan (Figure 1). The rate of the first step of the FKP reaction was tested by 




Figure 2.  Effect of sugar type and reaction conditions on FUT8 reaction rate and progress. A) 
One-pot (three steps) reaction utilizing in situ formed GDP-fucose (●) or GDP-azidofucose (■). 
B) One-step reaction utilizing purified GDP-fucose (●) or GDP-azidofucose (■). Reactions 
progress was followed by Q-TOF LC/MS analysis of intact protein and the peak intensities were 
used to calculate the percentage of conversion of the afucosylated IgG2 Fc glycoform into the 




During this assay, the rate of the FKP kinase step was measured for 6-azido-L-fucose and 
compared directly to that of the natural sugar, fucose. As expected and in agreement with the 
literature
28
, the rate of this step was about 8 times slower when using the modified sugar 6-azido-
L-fucose (Appendix: Figure B2). On the other hand, the second step of FKP is a reversible step 
and although we did not measure it directly, it also appeared to be slower when the modified 
sugar 6-azido-L-fucose is used instead of fucose during the chemoenzymatic synthesis of the 
corresponding nucleotide sugar (see appendix B for the chemoenzymatic synthesis of GDP-
azidofucose and also appendix A for the synthesis GDP-fucose). 
To speed up the functionalization of IgG2 Fc with 6-azido-L-fucose for bioorthogonal 
click reactions, the nucleotide sugar form of this sugar (i.e. GDP-azidofucose) was synthesized 
and purified as described in the appendix. Then, the purified nucleotide sugar was used directly 
in the functionalization reaction where only one step (the FUT8 step) is required to make the 
product. Before scaling up the production of the functionalized Fc (AzFuc-Fc), a small scale 
FUT8 reaction using the purified GDP-azidofucose was carried out and compared directly with a 
FUT8 reaction utilizing the natural nucleotide sugar GDP-fucose. This experiment was done to 
optimize the FUT8 functionalization reaction conditions and also as a measure of the 
promiscuity of FUT8 and its efficiency in transferring the modified sugar relative to the natural 
sugar. The reaction kinetics from these small scale reactions showed that FUT8 is quite 
promiscuous and transferred the modified sugar to the Asn297 glycan at only half the rate of the 
natural substrate under the same reaction conditions (Figure 2B). Afterward, a large scale 
reaction was carried out using the same reaction conditions to produce enough of the AzFuc-Fc 
to act as a substrate for site-specific conjugation studies using the bioorthogonal azide-alkyne 




was produced from 40 mg afucosylated Fc (90% yield). The purity and integrity of this 
functionalized Fc was confirmed by SDS-PAGE, while the homogeneity and the mass of the 
product were confirmed using intact protein LC-MS (Figure 3A). The calculated mass of AzFuc-







Figure 3. Initial characterization of IgG2 Fc variants using SDS-PAGE and Q-TOF LC/MS 
analyses under reducing conditions. SDS-PAGE lanes are as following: (1) 6-azido-L-fucose 
functionalized IgG2 Fc (AzFuc-Fc); (2) Propargyl-PEG4-acid-IgG2 Fc conjugate (Propargyl-





Preparation of site-specific IgG2 Fc conjugates using azide-alkyne cycloaddition 
The AzFuc-IgG2 Fc was then utilized in AAC conjugation reactions using polyethylene 
glycol (PEG) linkers functionalized with different alkynes (Figure 1A).  
One way we performed the conjugation was through the use of copper(I)-catalyzed  
azide-alkyne cycloaddition (CuAAC). In CuAAC, copper(I) acts a catalyst to promote the 
reaction between the azide and the linear alkyne to form a stable triazole linkage. The most 
common way to provide the reaction with copper(I) is by generating this metal in situ by 
reducing a copper(II) compound, such as CuSO4, by sodium ascorbate. Our first trials to perform 
the CuAAC using AzFuc-Fc and the alkyne propargyl-PEG4-acid did not go smoothly, as the 
protein started to aggregate and precipitate out of the solution shortly after starting the reaction. 
However, by including Tris(3-hydroxypropyltriazolylmethyl)amine (THPTA)
30,31
 in the reaction, 
no more aggregates were seen and the reaction proceeded smoothly towards the product as 
checked by intact protein mass spectrometry. However, as the reaction proceeds further towards 
the product, the protein started to undergo oxidation as evidenced by intact protein mass 
spectrometry (Appendix: Figure B3). In order to address the oxidation problem, we added an 
excess of free amino acids to the reaction mixture, such as methionine and arginine, to 
potentially intercept any reactive oxygen species. Reactive oxygen species generated by the 
copper(II) sulfate/ascorbate system are well known oxidizers of protein susceptible amino 
acids.
32
 However, the addition of these free amino acids did not appear to reduce the oxidation 
problem as shown from intact protein mass spectra (Appendix: Figure B4 and B5). Another way 
we tried to address the oxidation issue is through the use of copper(I) directly in the form of 
Cu(I)Br instead of the copper(II) sulfate/ascorbate system. Unfortunately, this trial did not appear 




 To solve the oxidation problem and produce the IgG2 Fc-propargyl conjugate (Propargyl-
Fc) necessary for subsequent studies described in this chapter, we tried to accelerate the CuAAC 
so that the conjugation reaction is completed in less than one hour. During the first hour of the 
reaction, and based on our preliminary reactions for optimizing the CuAAC, the IgG2 Fc did not 
exhibit a detectable level of oxidation as evidenced by the intact protein mass spectra. Therefore, 
a larger excess (about 2.5-fold) of the alkyne (propargyl-PEG4-acid) was used in the reaction 
mixture to drive the reaction to completion before any significant level of oxidation started to 
show up in the intact protein mass spectrum. By doing that, we were able to accelerate the 
reaction and make it completed in less than 40 minutes as shown in the Figure B7of the 
appendix. However, to remove the copper and prevent the formation of reactive oxygen species, 
the reaction mixture was immediately diluted with 15 volume of 1 mM EDTA in 50 mM HEPES 
buffer at pH 7.5. The reaction mixture was then concentrated back to initial volume using 
Amicon Ultra-15 centrifugal filter units. This process was repeated twice followed by dialysis of 
the reaction mixture in a suitable buffer for subsequent studies. The protein mass spectrum of the 
Propargyl-Fc conjugate prepared following this procedure showed no sign of oxidation (Figure 
3B), while the control Propargyl-Fc conjugate showed an extensive level of oxidation 
(Appendix: Figure B7D). 
 The other way to conjugate certain compounds through the 6-azido-L-fucose attached to 
the Asn297 glycan of IgG2 Fc in a specific manner is through the use of copper-free azide-
alkyne cycloaddition, which is widely known as strain promoted azide-alkyne cycloaddition 
(SPAAC).
33
 In one SPAAC reaction, we chose to use bicyclononyne (BCN) linker represented 
by BCN-PEG4-Acid (Figure 1A). This reaction was carried out by mixing the AzFuc-Fc with 




(BCN) is the driving force for the reaction to proceed forward towards the formation of the 
conjugate without the need for copper(I). The reaction progress was followed using intact protein 
LC-MS. Under the reaction conditions described in the materials and methods section (380 µM 
BCN linker) of this chapter, the reaction required two days for full conjugation of the BCN 
linker to Asn297 glycan of IgG2 Fc (Figure 3C). To confirm the conjugation site specificity, the 
resultant IgG2 Fc-BCN conjugate (BCN-Fc) was subjected to PNGase F digestion followed by 
intact protein mass spectrometry analysis. The mass spectrum showed a single peak 
corresponding to the mass of the deglycosylated IgG2 Fc (Appendix: Figure B8). 
In another SPAAC reaction, we chose to use dibenzocyclooctyne (DBCO) linker 
represented by DBCO-PEG5-acid. Again, the reaction was carried out by simply mixing of 
AzFuc-Fc with excess DBCO linker (25 µM) in aqueous media using 50 mM HEPES buffer at 
pH 7.5. The reaction was quite efficient and full conjugation was achieved in 22 hours (Figure 
3D). Interestingly, the SPAAC reaction kinetics using DBCO linker was much faster than that 
when using the BCN linker despite the fact that the concentration of BCN linker was more than 
15 times higher than the concentration of the DBCO linker in these reactions. The site of 
conjugation in DBCO-Fc conjugate was also confirmed by PNGase F digestion and intact 
protein mass spectrometry analyses (Appendix: Figure B8). 
Characterization and studies of the conjugates 
Dynamic light scattering 
The hydrodynamic sizes of all IgG2 Fc variants (functionalized Fc, Fc-conjugates, and 
deglycosylated Fc) in 20 mM phosphate buffer (pH 6.0) were measured using dynamic light 




of large aggregates (Appendix: Figure B9) and low polydispersity (< 15%) values suggesting a 
monodisperse size distribution. As shown in Figure 4, hydrodynamic diameters of Fc variants 
were found to be between 6.9 and 7.5 nm. The size of the AzFuc-Fc (6.99 ± 0.05 nm) and the 
deglycosylated Fc (6.93 ± 0.03 nm) were found to be similar (p=0.13) showing that the removal 
of glycans had no significant influence on protein hydrodynamic sizes. This is presumably 
because the Asn297 glycans are buried between the CH2 domains as they appear in most IgG Fc 
crystal structures.
34–36
 However, the sizes of the DBCO-, Propargyl-, and BCN-conjugates were 
7.47, 7.44, and 7.21 nm, respectively, reflecting a slight increase in the size of the Fc upon 
conjugating the corresponding linker to the Asn297 glycan. 
Comparison of thermal stability 
The secondary structure stability of the prepared Fc variants in response to increasing 
temperature (10 to 90 ⁰C) in 20 mM phosphate buffer (pH 6.0) was evaluated using Far-UV CD 
spectroscopy. As shown in Figure B10 of the appendix, CD spectra of all Fc variants showed 
minima around 216 nm indicating as expected primarily beta-sheet structure in the samples at 10 
⁰C. A strong negative shoulder is also seen at 230 nm due to tryptophan. The mean residue molar 
ellipticity at 218 nm was plotted as a function of temperature to monitor the loss of secondary 
structure during thermal stress. As shown in Figure 5A, the CD signal of protein samples became 
more negative above 60 °C indicating a loss of protein secondary structure. The order of Tm 
values is as following: AzFuc-Fc, DBCO-Fc, Propargyl-Fc > BCN-Fc > deglycosylated Fc 
(Figure 5E and Table B1 of the appendix). No significant difference in Tm values among AzFuc-
Fc, DBCO-Fc, and Propargyl-Fc was observed. In contrast, the deglycosylated Fc showed a 






Figure 4. Hydrodynamic diameter of various IgG2 Fc variants prepared in this work as 
determined by dynamic light scattering (DLS). Measurements were conducted at 25 °C with each 
Fc variant prepared in 20 mM phosphate buffer (pH 6.0) at 1 mg/ml concentration. Error bar 






Figure 5. Thermal unfolding profiles of IgG2 Fc variants in 20 mM phosphate buffer (pH=6.0) 
measured by: A) Far-UV circular dichroism; B) Intrinsic fluorescence sum; C) Intrinsic 
fluorescence moment; D) Extrinsic fluorescence (Sypro Orange). E) Corresponding Tm values 
obtained from these biophysical techniques. Error bars indicate standard deviation (N=3). 
 
The protein tertiary structure was studied using time-resolved intrinsic tryptophan 
fluorescence. The fluorescence intensity and lifetime of tryptophan is sensitive to the polarity of 
its surrounding environment. A total of 8 tryptophan residues reside at various locations in an Fc 
molecule and monitoring tryptophan fluorescence is therefore a sensitive measurement of 
alterations in protein tertiary structures. Sum and moment reflect the fluorescence intensity and 
“intensity-averaged” lifetime, respectively and were plotted as a function of temperature (Figure 
5B and C). Sum plot suggests that AzFuc-Fc and Propargyl-Fc have the highest Tm values, 




between the Tm values of AzFuc-Fc, DBCO-Fc, Propargyl-Fc and BCN-Fc, while 
deglycosylated Fc has the lowest Tm value as seen in CD measurements (Figure 5E and Table B1 
of the appendix).  
Sypro Orange dye, as an extrinsic fluorescence probe, is weakly fluorescent in water and 
becomes highly fluorescent when it binds to hydrophobic regions of proteins during protein 
unfolding. The intensity of Sypro Orange at 610 nm reflects the overall exposure of hydrophobic 
regions of protein and is therefore used to monitor protein tertiary structural alterations.
37
 AzFuc-
Fc, Propargyl-Fc, and BCN-Fc showed the highest thermal stability with no significant 
differences among their Tm values. In contrast, the Tm of DBCO-Fc is lower by 1 ⁰C indicating a 
slight destabilization effect of DBCO-linker on protein tertiary structure (Figure 5D, E and Table 
B1 of the appendix). The deglycosylated Fc again had the lowest thermal stability.   
The overall conformational stability of Fc variants was studied using differential 
scanning calorimetry (DSC). DSC thermograms show two distinct thermal transitions for all Fc 
samples (Figure 6). The first and second thermal transitions originate from the unfolding of CH2 
and CH3 domains, respectively. AzFuc-Fc, Propargyl-Fc, and BCN-Fc showed no difference in 
their Tm1 values (Appendix: Table B1). Compared to AzFuc-Fc, DBCO-Fc is less stable by 0.6 
°C with respect to Tm1. AzFuc-Fc, DBCO-Fc, Propargyl-Fc, and BCN-Fc shared similar Tm2 
values suggesting that the conjugation did not significantly affect the thermal stability of the CH3 





Figure 6. Thermograms and domains (CH2 and CH3) melting temperatures of IgG2 Fc variants in 
comparison with 6-azido-L-fucose-functionalized IgG2 Fc (AzFuc-Fc) as measured by 
differential scanning calorimetry. Error bars indicate the standard deviation of 3 replicates and 
statistical significance (*) compared to the AzFuc-Fc with a p value < 0.01 is indicated. Samples 
were at 0.5 mg/mL in 20 mM phosphate buffer (pH=6.0). 
 
Effect of conjugation chemistry on the conjugate solubility 
The apparent solubility (thermodynamic activity) of the prepared conjugates was assessed 
using a PEG-precipitation assay described previously
38–40
 and compared to that of the 
functionalized IgG2 Fc with no conjugation as shown in Figure 7. In this assay, polyethylene 
glycol (PEG) was used to decrease the solubility of the protein present at low concentration in a 




volume mechanism. Plotting the results from this assay resulted in a sigmoidal curve. Although 
these PEG-curves can provide a qualitative way for comparing solubility, the solubility of 
closely related proteins or the same protein under different formulation conditions can be 
compared in a quantifiable manner using the %PEGmidpt and the apparent solubility 
(thermodynamic activity). The %PEGmidpt is the weight %PEG required to reduce the protein 
concentration to 50% of its initial value while the apparent solubility (thermodynamic activity) is 
calculated by curve fitting and extrapolation to zero PEG concentration.  
The assay showed a mild increase (p<0.05) in the %PEGmidpt of the propargyl-conjugate 
compared to the AzFuc Fc; conversely there was a mild decrease (p<0.05) in the %PEGmidpt due 
to the conjugating of the DBCO and BCN linkers to the AzFuc Fc. As expected, a larger 
decrease in %PEGmidpt was observed for the deglycosylated IgG2 Fc when compared to the 
glycosylated Fc.
39
 Results from apparent solubility (thermodynamic activity) calculations 
showed the same trend of relative solubility predicted based on %PEGmidpt. However there was 
no difference (p<0.05) in the apparent solubility (thermodynamic activity) of the BCN conjugate 
when compared to the functionalized Fc. Overall results from PEG-precipitation assay predict a 
decrease in the solubility of DBCO-Fc, BCN-Fc, and deglycosylated Fc and an increase in the 






Figure 7.  (A, B, C, and D) Comparison of the PEGcurves (protein vs. PEG concentration) of 
different IgG2 Fc variants (DBCO-Fc, Propargyl-Fc, BCN-Fc, and deglycosylated Fc) to AzFuc-
Fc. E) Comparison of PEGmidpt values (w/v) of IgG2 Fc variants to AzFuc-Fc. F) Comparison of 
apparent solubility (thermodynamic activity) of each of IgG2 Fc variants to AzFuc-Fc. Error bars 
indicate the standard deviation of 3 replicates and statistical significance (*) compared to the 





Comparison of binding to Fc gamma receptors 
The binding kinetics and affinity of the conjugates to Fcγ receptors were assessed using 
biolayer interferometry (BLI) and compared to the binding kinetics and affinity of the 
functionalized Fc (AzFuc-Fc). The purpose behind conducting these binding studies was to 
check for any possible Fc conformational changes or steric interference due to conjugating these 
linkers, on the binding to these receptors. Previous studies have shown that the human IgG2 
subclass of antibodies binds weakly to most of Fcγ receptors however it shows a considerable 
binding to FcγRIIa.
41
 The binding of IgG2 to FcγRIIa is also affected by the naturally occurring 
polymorphism within this receptor where it has a stronger binding affinity for the H131 variant 
(FcγRIIa-H131) of the receptor than the R131 variant (FcγRIIa-R131).
41–43
 Both FcγRIIa 
receptor variants were used in our binding studies in addition to the high affinity FcγRIIIa 
variant (FcγRIIIa-V158). Binding of IgG to FcγRIIIa is also known to be reduced by the 
presence of α1,6- fucose (core fucose) on the Asn297 glycan of IgG.
44–46
 
Representative binding sensorgrams for binding of the AzFuc-Fc and the conjugates are 
shown in Figure 8. Also the calculated binding constants are shown in Table I. Based on these 
binding results, the affinity constant (KD) of the azidofucose containing IgG2 Fc lies in the 
micro-molar range affinity (2.23 µM) consistent with previously reported KDs for binding of 
IgG2 Fc to FcγRIIa-H131 and suggesting no significant change in the affinity of IgG2 Fc upon 
functionalization (chapter 2). Interestingly, the binding of DBCO-Fc to FcγRIIa-H131 (KD= 6.13 
µM) was reduced by 1.4-fold (p<0.05) compared to binding of the AzFuc-Fc to the same 
receptor variant. However, there was no statistical difference (p<0.05) in the affinities of the 
BCN-Fc and Propargyl-Fc to this receptor compared to the functionalized Fc. On the other hand, 




affinity to the FcγRIIa-R131 variant where the KD of the AzFuc-Fc was 14.1 µM (6-fold bigger 
compared to binding to FcγRIIa-H131 variant). All the conjugates showed similar (p<0.05) KDs 
to FcγRIIa-R131. Finally, the functionalized Fc and the conjugates showed a very weak binding 






Figure 8. Biolayer interferometry (BLI) analyses of IgG2 Fc variants binding to Fcγ receptors. 
(A), (B), and (C) represents binding to immobilized FcγRIIa-H131, FcγRIIa-R131, and 
FcγRIIIa-V158, respectively. Binding curves in (A) correspond to IgG2 Fc variants 
concentrations of 4, 2, 1, and 0.5 µM from top to bottom. Binding curves in (B) corresponds to 




(C) corresponds to IgG2 Fc variants concentration of 70 µM. (D) comparison of affinity 
constants (KDs) of IgG2-Fc variants to FcγRIIa-H131 and FcγRIIa-R131. Error bars indicate the 
standard deviation of 3 replicates and statistical significance (*) compared to the AzFuc-Fc with 
a p value < 0.05 is indicated. 
 
Table I. Kinetic rate and affinity constants for binding of IgG2 Fc variants to Fcγ receptors 


























AzFuc-Fc 833 ± 171. 1.86 ± 0.10 2.23 ± 0.47 320 ± 98.6 4.52 ± 0.70 14.1 ± 4.8 
DBCO-Fc 380 ± 60.5 2.33 ± 0.19 6.13 ± 1.10 203 ± 26.5 3.78 ± 0.88 18.6 ± 4.9 
Propargyl-Fc 726 ± 94.7 2.16 ± 0.15 2.98 ± 0.44 205 ± 44.1 3.43 ± 0.28 16.7 ± 3.8 




 During the past few years there has been a growing interest in designing site-specific 
ADCs.
2,7–11,47
 Many methods have been reported to achieve this goal and each method has its 
own advantages and disadvantages. Some of these methods utilized the Asn297 glycan of the 
antibody as a site for biorthogonal functionalization and specific conjugation.
11
 One way of 
functionalization of this glycan is through the introduction of a modified sugar unit with a 
suitable handle within the structure of this glycan using enzymes. Another way of introducing a 
handle within this glycan is through the use of chemical reagents to chemically modify certain 




this glycan by an α1,6- linkage would result in an antibody with two handles and a possibility of 
DAR of 2, a widely targeted DAR in many recent studies.
20,48–50
 To the best of our knowledge, 
only two trials focused on utilizing core fucose for site-specific conjugation. In one trial, Okeley 
et al. (2013)
20
 introduced several modified fucose units, especially 6-thifucose, on this glycan by 
feeding the mammalian cells producing the antibody with the acetylated form of the modified 
fucose units. Even though the trial was somewhat successful, unfortunately the incorporation 
efficiency of the thiofucose was only about 60% where the rest of the Asn297 glycan was either 
modified with the natural fucose or left afucosylated. In the second trial, Zuberbühler et al. 
(2012) developed a method to selectively oxidize the cis diol of core fucose of Asn297 glycan 
using sodium metaperiodate to introduce an aldehyde handle within this glycan for subsequent 
reaction with hydrazide linkers and form hydrazone linkages.
19
 Their functionalization method 
however relied on the use of harsh reaction conditions; oxidizing agents and low pH (pH 4.0). 
The oxidation was difficult to control and some of the fucose cis diols were over-oxidized to 
carboxylic acids making them unavailable to react with the hydrazide linkers. The other problem 
of subjecting the antibody to oxidation is the possibility of oxidizing some amino acids within 
the antibody. Some of these amino acids are critical for FcRn binding and the antibody 
pharmacokinetics and their oxidation results in reducing the antibody and ADC biological half-
life, such as Met-252 and Met-428.
18,51
 
 Our approach of functionalizing the Asn297 glycan for site-specific ADCs was through 
the core fucose residue. Efficient and complete introduction of a modified fucose was achieved 
in this work through the use of α1,6-fucosyltransferase (FUT8), a mammalian 
glycosyltransferase responsible for adding the natural sugar fucose to the first GlcNAc of the 
pentasaccharide core structure of N-linked glycans.
26




characterized in our laboratory using a novel way in E. coli. The enzyme was also used 
successfully in generating of fully fucosylated IgG2 Fc as shown in chapter 2. We sought to 
introduce a modified fucose with a suitable handle to fully functionalize the Asn297 glycan of 
IgG2 Fc for site-specific conjugation. An elegant fucose handle would be the bioorthogonal 
azide or alkyne handles to allow a click chemistry conjugation, such as 6-azido-L-fucose and 6-
alkynyl-L-Fucose. However, based on previous studies, it has been shown that the 6-Alkynyl-L-
fucose analogue has low incorporation efficiency and could also behave as an inhibitor of 
FUT8.
20,52
 In addition to this limitation, the 6-Alkynyl-L-fucose would provide a lower 
flexibility and allow only the copper catalyzed version of the biorthogonal azide-alkyne 
cycloaddition reaction (i.e. CuAAC), while the 6-azido-L-fucose would allow both versions of 
AAC, i.e. the Strain prompted azide-alkyne cycloaddition (SPAAC) as well as CuAAC. Our 
initial trials included the use of one-pot reaction containing FUT8 and FKP to transfer the 
modified fucose (6-azido-L-fucose) from the GPD-azidofucose, formed in situ from FKP 
reaction, to the Asn297 glycan of IgG2 Fc by the action of FUT8 in a similar way of making 
fully fucosylated IgG2 Fc described in chapter 2. Although using this one-pot strategy resulted in 
efficient incorporation of the 6-azido-L-fucose in the Asn297 glycan, the process was much 
slower (more than 9 days) compared to the incorporation of the natural sugar fucose under the 
same reaction conditions (2 days), making it less convenient for generating site-specific ADCs. 
Subsequent investigations to determine the step(s) that are responsible for this slowness in the 
one-pot reaction led us to make and purify GDP-azidofucose and use it directly in FUT8 
reaction. The result was efficient functionalization of the Fc in less than 24 hours. Using purified 
GDP-azidofucose does not only skip the slowness in making this activated nucleotide sugar in 




and inorganic pyrophosphate that can be formed during FKP reaction and act as inhibitors for 
FUT8.
26
   
 Stability of the linkage between the antibody and the payload represent a critical factor in 
the safety and efficacy of ADCs. The AAC has been widely used in recent studies as an 
alternative to conventional conjugation chemistry in making site-specific ADCs. Although in 
most of these studies
13,23,53
 the authors preferred to use the SPAAC version of AAC over the use 
of CuAAC, an optimized CuAAC process, as the one we carried out in this work, can add 
another dimension and give more flexibility in using click chemistry conjugation reactions to 
make site-specific ADCs. The AAC is a highly specific conjugation reaction which can be 
carried out efficiently in neutral aqueous solutions containing the protein of interest.
11,30,54
 This 
reaction results in the formation of a stable triazole linkage between the alkyne and the azide. 
Premature release of the payload has been shown to occur in the plasma when using thiol-
maleimide chemistry in constructing ADC, due to retro-Michael reaction.
48
 Thiol-maleimide 
chemistry has been utilized in making the commercial products Kadcyla and Adcetris as well as 
utilized in many experimental ADCs such as the one developed by Okeley et al. (2013).
20
 Also, 
premature release of the payload from ADC made through a liable hydrazone linkage, as the one 
developed by Zuberbühler and described above, is likely to happen in the human plasma.
19,55
 The 
premature release of potent toxic payloads in the plasma can result in serious off-target toxicity 
and narrowing of therapeutic index of the corresponding ADC.
48,56
 Therefore, new chemistries 
such as AAC have been used recently in making next generation ADCs to solve these stability 
problems along with other shortcomings associated with first generation ADCs. The strategy we 
followed here which shows a full functionalization of the antibody Fc with an azido-modified 




 Similar to mAb therapeutics, the structural stability of the antibody part of an ADC is 
critical for the stability of these therapeutic products and prevention of aggregation which results 
in loss of activity and potential immunogenicity reactions when introduced into biological 
systems.
57,58
 Introducing a linker and a toxin on the mAb is expected to alter the structure of the 
mAb part of the ADC and can reduce the stability of the product compared to the naked mAb; 
however this effect is also expected to be highly dependent on the site of conjugation.
59,60
 In a 
study of trastuzumab-DM1 (commercially became Kadcyla), Wakanker et al. (2010) showed that 
the conjugation of DM1 to trastuzumab resulted in reducing the thermal stability of the 
intermediate (mAb-linker) and the product (mAb-linker-toxin) by about 2 and 4.4 °C, 
respectively as measured by differential scanning calorimetry.
61
 This reduction in the thermal 
stability was also accompanied by an increase in the aggregation propensity of these modified 
forms of trastuzumab. Accordingly, we sought to test the impact of using different linkers having 
different physicochemical properties on the overall conjugate secondary and tertiary structure 
thermal stabilities using a variety of biophysical techniques.
62
 The alkyne parts of the used 
linkers are among the most commonly used alkynes in AAC reactions both the CuAAC and 
SPAAC. The biophysical techniques used to probe the effect of conjugation are widely used in 
our laboratories in probing the physical stability of proteins. Some techniques were able to detect 
differences among the tested IgG2 Fc variants while other techniques showed similarity in 
results. These techniques usually complement each other to find differences and similarities in 
proteins physical stability and some of them can be run in high throughput format to enable rapid 
screening of drug candidates. Among the noticeable differences was a reduction in thermal 
stability of the DBCO-Fc by 1 °C as detected by extrinsic fluorescence, and 0.6 °C as detected 




conjugate can be attributed to a mild structural perturbation of IgG2 Fc due the bulkiness and 
hydrophobicity of this cyclic alkyne compared to BCN and the linear alkynes. However, this 
reduction in the thermal stability is obviously less than a larger reduction in the thermal stability 
of the Fc upon the removal of the Asn297 glycan (i.e. deglycosylated Fc), which was used as a 
benchmark to assess the thermal stability of these conjugates. These structural stability studies 
could also suggest the ability of the Asn297 glycan as a conjugation site to accommodate 
compounds having different physicochemical properties without impacting the antibody stability 
significantly. 
 The physicochemical properties of an ADC are crucial in determining the safety, 
efficacy, and stability of this category of biologics.
58,63
 The site of conjugation and the DAR are 
important factors in determining an ADC’s physicochemical properties. For example, it has been 
shown that an ADC with a DAR of 4 is more effective and has a broader therapeutic index than a 
similar ADC with a DAR of 8, although the latter has more payload and theoretically should be 
more potent.
23,64
 The rationale behind this discrepancy resides in the fact that most of the ADC 
payloads and linkers are hydrophobic in nature. Hydrophobicity has been thought to be a 
property which allows these payloads escaping the lysosomal degradation and helps diffusion out 
to the site of action.
65,66
 However, the higher hydrophobicity of the ADCs having higher DAR 
can also lead to poor pharmacokinetics and higher uptake of the ADCs by non-target cells such 
as hepatocytes.
64
 Another possibility for poor pharmacokinetics of ADC with high DAR, 
especially ADCs prepared using random payload conjugation through the natural amino acid 
lysine, is the interruption of the antibody-FcRn recycling mechanism, which represent a unique 
process in elongating the half-life of the antibody-based therapeutics.
16–18
 Conjugation through 




the hydrophobicity of payloads and increase ADC stability.
39,64,66–68
 This is probably due to the 
hydrophilic nature of this sugar chain which has been shown to affect the solubility of antibodies 
significantly. Also, a higher solubility of an antibody therapeutic is usually desirable, especially 
when formulating a drug product for subcutaneous injection where the injection volume is 
relatively small and a highly concentrated protein needs to be formulated.
69
 In this work we 
demonstrated the effect of different linkers on the hydrophobicity of the prepared conjugate 
compared to the functionalized Fc using the PEG-precipitation assay, a high throughput assay 
which compares the apparent solubility (thermodynamic activity) of closely related proteins.
38–40
 
Although cyclic alkyne (DBCO and BCN) linkers resulted in some reduction in the Fc apparent 
solubility, interestingly the linear alkyne linker (propargyl) resulted in an increase in the Fc 
apparent solubility. Therefore, the type of the alkyne may also be considered when screening for 
ADC with better solubility profiles and linear alkynes may be a better choice and may minimize 
any further reduction in the solubility of the ADC upon conjugating a hydrophobic payload. On 
the other hand, the dramatic reduction in the deglycosylated IgG2 Fc solubility (thermodynamic 
activity) compared to the glycosylated Fc shown in this study and previous studies should be 
taken into consideration in studies where the removal or truncation of Asn297 glycan had to be 
done to enable site-specific conjugation.
23,50
  
 In an ADC, the main cytotoxic effect comes from the payload, while in a naked 
anticancer mAb the toxicity depends largely on the antibody effector functions such as 
ADCC.
70,71
 Therefore, many strategies have been adopted to enhance effector functions 
especially through glycoengineering of the Asn297 glycan by eliminating the core fucose.
72
 In an 
ADC, recruiting effector cells may not always be desirable since the uptake of the immune 




normal effector cells and hence narrowing the therapeutic index of the ADC.
1,70
 Recently, IgG 
subclasses with lower effector functions mediated through Fcγ receptors, such as human IgG2 
and IgG4, have been utilized in constructing ADCs to minimize this off-target toxicity.
2
 We 
chose the IgG2 Fc sequence in this study since it has the weakest binding to Fcγ receptors except 
for FcγRIIa. We wanted to test the effect of functionalizing IgG2 Fc and making these 
conjugates on the binding to these receptors. It is well known that binding to these receptors is 
highly affected by the Asn297 glycan. Removal of this glycan in general abrogates Fcγ receptor 
binding.
73,74
 Our results showed that the addition of 6-azido-L-fucose to the Asn297 glycan of 
IgG2 Fc reduced the binding to FcγRIIIa-V131 just like the natural sugar, fucose (chapter 2). 
Likewise, the conjugates showed no detectable binding to this receptor and hence lower 
probability of ADCC. On, the other hand the DBCO-conjugate showed a reduced affinity 
(KD=6.13 µM) to FcγRIIa-H131 compared to the naked Fc (KD=2.23 µM) which was mainly due 
to reduced association rate of the conjugate to this receptor variant. Again, the DBCO-linker has 
the biggest alkyne used in this study and has one extra PEG residue and the mild structural 
perturbation of the DBCO-conjugate shown in this study by the DSC and extrinsic fluorescence 
and/or a possible steric hindrance of the Fc/receptor interaction may explain this reduced affinity. 
Any possible further reduction in binding to Fcγ receptors after adding the required payload, and 
hence lower effector function, could also be advantageous.
70
 From this perspective, and from the 
perspective of faster conjugation kinetics of DBCO-linker compared to BCN-linker, the DBCO-
linker might be a better choice in making site-specific ADCs through this strategy. 
 In conclusion, we developed a method for site-specific conjugation through the Asn297 
glycan of IgG for a potential use in the development of next generation ADCs. In this method, 




modified fucose with a biorthogonal handle suitable for click chemistry conjugation. To 
demonstrate the suitability of this handle for conjugation, we used different linkers 
functionalized with different alkynes for site-specific conjugation through this handle. All of 
these linkers showed excellent conjugation efficiency and resulted in the formation of 
homogeneous conjugates under mild reaction conditions. The conjugates were also tested for any 
possible impact of the linkers added at this site on the structural stability, solubility and binding 
properties of the naked IgG2 Fc. These properties were tested in a systematic way using 
complementary biophysical analytical techniques, solubility assessment assay, and BLI-based 
binding studies. Therefore a combination of our synthetic platform, which can be used to 
produce highly homogeneous conjugates, with the experimental set up described here could 
represent a powerful approach to screen for the impact of linkers or linker-drug on ADC 
properties during different stages of drug development. Results from this study suggests the use 
of linear alkyne-based linkers coupled with optimized CuAAC to avoid a larger solubility 
reduction and destabilization issues that might be associated with using cyclic alkynes-based 
linkers. However, if the destabilization effect due to DBCO-based linkers and solubility are 
considered to be acceptable then linkers of this type might be preferred over others due to the 
fast conjugation kinetics and possibility of reduced effector functions mediated through Fcγ 
receptors. If SPAAC is intended to be used without even mild reduction in ADC stability, 








Materials and methods 
Materials 
GDP-fucose produced in house as shown in chapter 2. Amicon Ultra-15 Centrifugal Filter Units 
with a molecular weight cutoff of 10 Da were purchased from EMD Millipore (Billerica, MA). 
Protein G resin was produced as described previously.
74,75
 CuSO4 was obtained from Alpha 
Aesar (Tewksbury, MA). UDP-GlcNAc, Inorganic pyrophosphatase from baker's yeast (S. 
cerevisiae), NADH, Pyruvate Kinase/Lactic Dehydrogenase enzymes from rabbit muscle, ATP, 
GTP, L-fucose, and sodium ascorbate, were obtained from Sigma-Aldrich (St. Louis, MO). 6-
azido-L-fucose was purchased form Apollo Scientific (Denton, Manchester). DBCO-PEG5-
Acid, endo-BCN-PEG4-Acid, and Propargyl-PEG4-Acid were purchased from Broadpharm (San 
Diego, CA). Deglycosylated IgG2 Fc was prepared as described in chapter 2 by treating 
glycosylated IgG2 Fc with PNGase F. 
Production of afucosylated IgG2 Fc 
A homogeneous afucosylated glycoform of IgG2 Fc as a substrate for FUT8 catalyzed 
reaction (Figure 1 A) was produced in our laboratory as described in chapter 2. Briefly, the DNA 
sequence corresponding to the amino acid sequence of human IgG2 Fc (C226PPC…..SPGK447, 
Eu numbering) was subcloned into pPICZαA (EasySelect
TM 
Pichia Expression Kit, Invitrogen) 
plasmid for expression in the methylotrophic yeast Pichia pastoris. The IgG2 Fc is then purified 
from the growth media via protein G affinity chromatography followed by hydrophobic 
interaction chromatography and weak cation exchange for further purification and 
homogenization. Then the high mannose IgG2 Fc glycoform obtained from yeast expression was 





Functionalization of IgG2 Fc Asn297 glycan  
On-pot reaction 
 A one-pot reaction using FKP and FUT8 (Figure 1) was followed for site-specific 
addition of the modified sugar 6-azido-L-fucose to the Asn297 glycan of IgG2 Fc as following. 
First, the FKP reaction was carried out in 50 mM Tris HCl pH 7.5 buffer containing ATP (5 
mM), GTP (5 mM), 6-azido-L-fucose (5 mM ), MgCl2 (5 mM), and FKP (120 µg/ml) at room 
temperature to generate the activated sugar GDP-azidofucose. After 12 hours, the FKP reaction 
mixture was added to an equal volume (250 µl) of the hybrid IgG2 Fc (2.5 mg/ml Fc in 20 mM 
Tris HCl buffer pH 7.5) solution. The transfer of 6-zido-L-fucose from GDP-azidofucose 
generated in situ to the IgG2 Fc Asn297 glycan was then initiated by adding 1.2 µU (10 µg) of 
FUT8 produced in E. coli as described in chapter 2.The reaction was incubated at 30 °C and 
monitored for progress using Q-TOF LC/MS. This one-pot reaction eventually went to 
completion; however it required nine days to convert all the afucosylated Fc into AzidoFucose-
modified Fc (AzFuc-Fc) as shown in Figure B1 of the appendix. 
Reaction utilizing purified GDP-azidofucose 
 GDP-azidofucose was synthesized chemoenzymatically and purified from the reaction 
mixture as described in details in appendix B. Then the purified nucleotide sugar was used in 
FUT8-catalyzed reaction for the functionalization of the Asn297 glycan of IgG2 Fc as following. 
Before the reaction, afucosylated IgG2 Fc was dialyzed against 20 mM HEPES buffer pH 7.5. 
The reaction mixture (20 ml) containing afucosylated IgG2 Fc (2 mg/ml), GDP-azidofucose (1 
mM), and 130 µU of FUT8 was incubated at 30 °C. The reaction was monitored by Q-TOF 




mixture was diluted with 20 mM MES buffer pH 6.2 (equilibration buffer) to a final IgG2 Fc 
concentration of 0.1 mg/ml. Then, the diluted Fc solution is loaded into a protein G column (10-
ml bed volume protein G column), pre-equilibrated with equilibration buffer, using a loading 
flow rate of 6 ml/min. The flow-through is also loaded into the column to ensure full recovery of 
the Fc from the reaction mixture. The column is then washed with 5 CV of the equilibration 
buffer followed by 5 CV of the equilibration buffer containing 500 mM NaCl. A final wash step 
using 5 CV of the equilibration buffer is also conducted to get rid of the high salt concentration. 
Eluting IgG2 Fc was done by using 100 mM glycine buffer, pH 2.7 and the protein solution is 
immediately neutralized using 1M Tris HCl buffer, pH 9.0. The expected mass of the 
functionalized IgG2 Fc is 26461.1 Da and the observed mass was 26459.6 Da (Figure 3A). In 
this process, 36 mg of the AzFuc-IgG2 Fc was produced which corresponds to a yield of 90%. 
Preparation of site-specific IgG2 Fc conjugates using azide-alkyne cycloaddition 
Production of the Propargyl conjugate 
 The propargyl-PEG4-acid was conjugated to AzFuc-IgG2 Fc using CuAAC to produce 
Propargyl-Fc conjugate (Figure 1A). Before the reaction, the afucosylated IgG2 Fc was dialyzed 
in 50 mM HEPES buffer pH 7.5. Also, a 20 mM propargyl-PEG4-Acid stock solution was 
prepared by dissolving the required amount of propargyl-PEG5-acid in deionized water. The 
solutions of CuSO4 (20 mM), THPTA (50 mM), and sodium ascorbate (100 mM) were prepared 
freshly before the reaction by dissolving the required amount of these reagents in deionized 
water. Then, the CuAAC reaction was carried out as following. The afucosylated IgG2 Fc was 
mixed with propargyl-PEG4-acid in a separate vial prior to the reaction to achieve a final 




respectively. On the other hand, the freshly prepared CuSO4 was mixed with THPTA in a 
separate vial to achieve a final reaction concentration of 0.2 mM and 1 mM of CuSO4 and 
THPTA, respectively. Then both solutions were mixed together and the reaction was started by 
adding the freshly prepared sodium ascorbate to a final reaction concentration of 5 mM. The 
reaction was incubated at room temperature for 40 minutes then immediately followed by adding 
15 volumes of EDTA solution (1 mM in 50 mM HEPES pH 7.5 buffers) to 1 volume of the 
reaction mixture. Then, the mixture was concentrated back to initial volume using Amicon Ultra-
15 Centrifugal Filter Units. The dilution and concentration step of the reaction mixture was 
repeated one more time then followed by dialysis in the required buffer for subsequent studies. In 
this process, 6 mg of propargyl-conjugate was obtained from 6.5 mg AzFuc-Fc which 
corresponds to a yield of 91%. The conjugate purity and integrity was checked using SDS-PAGE 
gel. The expected mass of the propargyl-conjugate is 26720.1 Da and the observed mass was 
26718.9 Da as shown Figure 3B. 
Production of the BCN-conjugate 
The BCN-PEG4-acid was conjugated to AzFuc-IgG2 Fc using SPAAC to produce BCN-
Fc conjugate (Figure 1A). Before the reaction, the AzFuc-Fc was dialyzed in 50 mM HEPES 
buffer pH 7.5. Also, a 7.5 mM BCN-PEG4-acid stock solution was prepared by diluting the 
BCN-PEG4-acid solution in DMSO (75 mM) with distilled water (1:10 dilution). Then the 
reaction was carried out by mixing the AzFuc-Fc and BCN-PEG4-acid to final concentrations of 
7.5 µM and 380 µM, respectively. The reaction was incubated at room temperature and checked 
for progress by intact protein mass spectrometry. After two days, the reaction mixture was 
diluted with 15 volumes of 50 mM HEPES buffer pH 7.5 to get rid of excess alkyne then 




followed by dialysis in the required buffer. In this process, 6.2 mg of BCN-conjugate was 
obtained from 6.5 mg AzFuc-Fc which corresponds to a yield of 94%. The integrity and purity of 
the BCN-conjugate was checked by SDS-PAGE gel. The expected mass of the BCN-conjugate is 
26901.5 Da and the observed mass was 26897.1 Da as shown in Figure 3C. 
Production of the DBCO-conjugate 
The DBCO-PEG5-acid was also conjugated to AzFuc-IgG2 Fc through the SPAAC 
reaction to produce DBCO-Fc conjugate as shown in Figure 1A. Again, before the reaction, the 
AzFuc-Fc was dialyzed in 50 mM HEPES buffer pH 7.5. Also, a 4.5 mM DBCO-PEG5-acid 
stock solution was prepared by diluting the DBCO-PEG5-acid solution in DMSO (4.5 mM) with 
distilled water (1:10 dilution). Then the reaction was carried out by mixing the AzFuc-Fc and 
BCN-PEG4-acid to final concentrations of 7.5 and 25 µM, respectively. The reaction was 
incubated at room temperature and checked for progress by intact protein mass spectrometry. 
After 22 hours, the reaction mixture was diluted with 15 volumes of 50 mM HEPES buffer 
(pH=7.5) to get rid of excess alkyne and concentrated back to the original reaction volume using 
Amicon Ultra-15 Centrifugal Filter Units followed by dialysis in the required buffer. In this 
process, 6.2 mg of BCN-conjugate was obtained from 6.5 mg AzFuc-Fc which corresponds to a 
yield of 93%. The integrity and purity of the DBCO-conjugate was checked by SDS-PAGE gel. 
The expected mass of the BCN-conjugate is 27056.6 Da and the observed mass was 27052.5 Da 
as shown in Figure 3D. 
Dynamic light scattering 
Dynamic light scattering (DLS) was performed using a DynaPro plate reader (Wyatt 




into 20 mM phosphate buffer (pH 6.0). The samples were analyzed at a concentration of 1 
mg/ml. Samples were loaded into a 384 well flat clear bottom black plate (Corning Incorporated, 
Corning, NY) and each sample was measured five times with an acquisition time of 30 sec each 
time. The measurement was performed at 25 ⁰C by illuminating the samples with a 
semiconductor laser of 830 nm-wavelength, and the intensity of scattered light was measured at 
an angle of 158°. A viscosity value of 1.019 cP was used to calculate the hydrodynamic 
diameter. The data was processed using a regularization analysis and intensity averaged diameter 
values were reported.  
Far-UV Circular dichroism 
Far-UV circular dichroism (CD) was performed using a Chirascan-plus CD spectrometer 
(Applied Photophysics, Leatherhead, UK) equipped with a 6-position, peltier-controlled cell 
holder. IgG2 Fc variants were dialyzed overnight at 4 ⁰C into 20 mM phosphate buffer (pH 6.0). 
The samples were analyzed at a concentration of 0.2 mg/ml. The CD spectra of each IgG2 Fc 
variant were recorded from 190 to 260 nm in 1-nm increment using a 1-mm pathlength quartz 
cuvette. The temperature ramp was set from 10 to 90 ⁰C with an increment of 2.5 ⁰C per step and 
an equilibration time of 2 min at each temperature. The mean residue molar ellipticity at 218 nm 
was plotted as a function of temperature and Tm values were determined by a first-derivative 
method using Origin 2017 (OriginLab; Northampton, MA). The same method was used to 
calculate Tm values for the following studies unless noted otherwise. 
Extrinsic fluorescence 
An extrinsic fluorescence melting study was performed with an Mx3005P qPCR system 




at 4 ⁰C into 20 mM phosphate buffer (pH 6.0). Sypro Orange dye stock (5000x) (Invitrogen, 
Carlsbad, CA) was added into protein solution (0.2 mg/ml) at a dilution factor of 1000. Protein 
samples were excited at 492 nm and emission was collected at 610 nm. Samples were heated 
from 25 to 99 ⁰C using a 1 ⁰C step size and an equilibration time of 2 min at each temperature. 
The emission intensity was plotted as a function of temperature and Tm values were determined.  
Time-resolved intrinsic fluorescence 
The time-resolved intrinsic fluorescence of each IgG2 Fc variant was measured using a 
fluorescence lifetime plate-reader (Fluorescence Innovations, Minneapolis, MN) equipped with a 
tunable pulse dye laser and a RIC20 temperature controlled 384-well plate holder (Torrey Pines 
Scientific, Carlsbad, CA). The excitation wavelength was set at 295 nm and two emission filters 
(310 nm longpass and 360/20 nm band-pass) were placed before a photomultiplier tube detector. 
Protein samples (0.2 mg/ml in 20 mM phosphate buffer pH 6.0) were loaded into a 384 well 
black bottom plate (Hard-Shell, Bio-Rad, USA) and silicon oil was loaded onto protein samples 
to avoid sample evaporation during thermal melt. The thermal melt was run from 25 to 90 °C at 
2.5 °C intervals and samples were equilibrated for 2 min at each temperature. Fluorescence 
decay waveforms were recorded up to 100 ns. Two parameters (sum and moment) were 
determined from the raw waveform by the FII data analysis software (Fluorescence Innovations, 
Minneapolis, MN). The sum (in mV*ns) is the peak area under the waveform curve and 
represents the fluorescence intensity of the sample collected from the PMT detector. The 
moment (in ns) is the intensity-averaged time of the waveform plot and its mathematical 
definition was described previously.
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 Sum and moment were plotted as a function of 




Differential scanning calorimetry 
Differential scanning calorimetry (DSC) was performed using a MicroCal VP-Capillary 
calorimeter (Malvern, UK) equipped with an autosampler (MicroCal, LLC, Northampton, MA) 
and a sample tray holder. The temperature ramp was set from 10 to 100 °C at a scan rate of 60 
⁰C/hr. Protein samples (0.5 mg/ml in 20 mM phosphate buffer pH 6.0) were equilibrated for 15 
min at 10 ⁰C before each run and a filtering period of 16 sec was used. Thermal transitions were 
deconvoluted and apparent transition temperatures were calculated using a non-two-state 
equilibrium model in Origin 7.0 (OriginLab; Northampton, MA). 
PEG-precipitation assay 
The protocol for the high throughput version of the PEG assay for assessing apparent 
solubility (thermodynamic activity) of the prepared IgG2 Fc variants was adopted from Toprani 
et. al. (2016).
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 Stock solutions of 20 mM phosphate buffer,pH 6.0 and 20 mM phosphate buffer 
containing 40% w/v PEG-10,000 at pH 6.0 were mixed to prepare various concentrations of PEG 
solutions ranging from 0 to 40% w/v PEG. A volume of 80 µL of the various PEG-10,000 
solutions was added to wells of a 96-well polystyrene filter plate (Corning #3504, Corning Life 
Sciences, Corning, NY). All protein samples were dialyzed into 20 mM phosphate, pH 6.0 and 
then diluted to 1 mg/mL with the respective buffer. Twenty microliters (20 µL) of the protein 
stock solution (1 mg/mL) was then added to each well to a final protein concentration of 0.2 
mg/mL. The plates were incubated overnight at room temperature and then centrifuged at 3,500 
rpm (1,233 rcf) for 15 min and the filtrate was collected in a clear 96 well collection plate 
(Greiner Bio-One#655001, Greiner Bio-One North America Inc., Monroe, NC). Subsequently, 




filtrate was measured on a SpectraMax M5 UV-Visible plate reader (Molecular Devices, 
Suunyvale, CA) at 280 nm to determine the protein concentration.  
Curve fitting algorithm for PEGmidpt and apparent solubility determinations: 
The absorbance at 280 nm versus PEG-10,000 (% w/v) data were fit to a standard four-
parameter, modified Hill-slope sigmoidal curve equation using Python (x,y) v.2.7.6.0, an open 
source scientific and engineering development software based on python language.  
𝑦 = 𝑏 + (
𝑡−𝑏
1+ 𝑒 𝑠(𝑚𝑖𝑑−𝑥)
)                                  (1) 
where t= top plateau, b= bottom plateau, mid= x-axis midpoint, and s=slope. 
The %PEGmidpt values and apparent solubility value parameters were then calculated 
from the resulting curve fit as described in detail elsewhere.
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Fc gamma receptors binding assays  
The binding affinity and kinetics of the functionalized IgG2 Fc and the prepared IgG2 Fc 
conjugates to Fcγ receptors were assessed using biolayer interferometry (BLI). The receptors 
used in these binding studies (FcγRIIa-131H, FcγRIIa-131R, and FcγRIIIa-158V) were 
expressed in our laboratory using the yeast Pichia pastoris. The purified receptors were then 
subjected to biotinylation at their C-termini using sortase mediated ligation (chapter 2). Samples 
were dialyzed in PBS (50 mM sodium phosphate, 150 mM NaCl, pH 7.4) to perform the binding 
assays. Casein was added to all samples and buffers at a concentration of 1 mg/ml to block any 
possible non-specific binding. In these binding assays, the biotinylated receptor is first 
immobilized on a streptavidin biosensor (Pall ForteBio LLC) to a response level of 1 nm. A new 
baseline was then established by using a blank PBS solution. The sample solution is placed in the 
sample holder to acquire the association phase of the binding sensorgram for 30 seconds. 




dissociation phase for 20 seconds. In FcγRIIa-131H and FcγRIIa-131R binding assay, four 
different sample concentrations were used and the sensorgrams from these concentrations were 
used to fit the data and calculate the kinetic rate constants (ka and kd) and the equilibrium 
dissociation rate constant (KD). During the FcγRIIa-131H binding assay, the sample 
concentrations were 0.5, 1, 2, and 4 µM while in FcγRIIa-131R binding assay, the sample 
concentrations were 1.25, 2.5, 5, and 10 µM. In case of the FcγRIIIa-158V binding assay, a high 
sample concentration (70 µM) was tested for any possible binding to this receptor. The binding 
assays were performed at 25 °C and the data were fit using BLItz Pro software. 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed as previously described
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 using 12% gels. First, a protein 
sample of about 5 µg was mixed with the appropriate volume of a 3X reducing sample loading 
buffer (240 mM Tris HCl pH 6.8, 6% SDS, 30% glycerol, 2.3 M 2-Mercaptoethanol, and 0.04% 
bromophenol blue) and boiled for five minutes before loading into the SDS-PAGE wells. After 
loading, the gel was developed by a applying a voltage of 180 Volts for 55 minutes using Bio-
Rad power supply (PowerPac™ Basic Power). The protein bands were then visualized by 
staining the gel with Coomassie blue R-250 (Bio-Rad) solution for about one hour followed by 
an overnight destaining using a mixture of 25% methanol, 5% acetic acid, and 70% Millipore 
water. 
Intact protein mass spectrometry 
Agilent 6520 Accurate-Mass Q-TOF LC/MS equipped with ESI source was used to do all 
the mass spectrometry analyses described in this chapter as described below. The protein sample 




CA) to a final concentration of 10 mM. Then, 30 µl of the reduced protein sample was injected 
into a reverse phase C4 column, 50 mm, 4.6 mm I.D. (Vydac 214 MS, 300 A
°
 pore size, 5μm 
particle size) followed by a 5%-90% solvent B gradient elution development within 7 minutes at 
a flow rate of 0.5 mL/min. Solvent A was composed of 99.9% water, 0.08% formic acid, and 
0.02% trifluoroacetic acid while solvent B was composed of 99.9% acetonitrile, 0.08% formic 
acid, and 0.02% trifluoroacetic acid. Data acquisition was performed using Agilent Mass Hunter 
Acquisition software (Version B.02.00) while data analysis was performed using Agilent Mass 
Hunter Qualitative Analysis software (Version B.03.01). 
Statistical analysis 
Statistical analysis was done using unpaired t test to compare the different parameters. All 
statistical analyses were performed using GraphPad software. A p-value of less than 0.05 was 
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The highly-conserved N-glycan in the CH2 domain of IgG isotype (Asn297 glycan) has 
been shown to have a significant effect on the antibody properties. The Asn297 glycan supports 
the underlying protein backbone and helps in maintaining the right conformation of IgG. This 







physicochemical properties such as solubility of the antibody
5
, as well-as immunogenicity
7
. The 
challenge in producing an antibody with a homogeneous glycan (i.e. single glycoform) comes 
from the fact that the glycosylation process is not a template-driven cellular process.
8,9
 Unlike 
the DNA transcription and RNA translation, the N-glycosylation is mediated by a series of 
glycosyltransferases and glycosidases present at different locations and abundancies in the 
endoplasmic reticulum and Golgi apparatus. Therefore, during the protein journey through these 
organelles, it will be decorated with different sugars depending on the availability of these 
enzymes, availability of donor sugar substrates, protein transit time, and cell type. The net result 
is a production of a protein having different glycoforms. It is interesting to see a marketed 
monoclonal antibody (mAb) product as supposed to contain a single active pharmaceutical 
ingredient while in reality it can be a mixture of tens to hundreds of glycoforms that have the 
same amino acid sequence but different glycan composition. Therefore, to study each glycoform 
carefully, we need a robust method that can generate homogeneous glycoforms in sufficient 
quantities. 
Human IgG2 is a less-well characterized IgG subclass in terms of it Asn297 glycan. IgG2 
subclass has been utilized in making therapeutic mAb such as denosumab and panitumumab. The 
relatively low effector functions of this IgG subclass made it a viable choice for designing 
therapeutic mAb when the effector function mode of action is not needed or when the effector 




research studies were carried out recently with the aim of introducing more reduction in the 
effector functions of IgG2 through changing the amino acid sequence of the protein. Most of 
these mutagenesis studies were carried out on amino acids that participate directly or indirectly 
in the binding of IgG2 to the Fcγ receptors and C1q protein, a binding that can initiate cell-
mediated effector functions and activation of the complement system, respectively. IgG binds 
Fcγ receptors and C1q protein through the area of lower hinge region and upper CH2 domain 
which is highly affected by Asn297 glycan. In most of these studies, the Asn297 glycosylation 
profile was not taken into account especially the level of core fucosylation.
10
 In addition to that, 
there is always a potential immunogenicity associated with changing the amino acid sequence of 
a natural protein. Conversely, glycoengineering carries a lower immunogenicity potential and 
might be used alone or in combination with other approaches to pursue same goals. 
In order to study the effect of composition of Asn297 glycan on the properties of IgG2 
subclass, we developed an enzymatic synthesis approach to produce homogeneous and highly 
purified IgG2 Fc glycoforms. Before this synthesis, we cloned the Fc region of the human IgG2 
subclass in a suitable vector for expression of this glycoprotein in the glycosylation-deficient 
yeast Pichia pastoris to produce relatively large laboratory-scale quantities of IgG2 Fc. The 
Pichia pastoris glycosylation machinery produced a well-characterized IgG2 Fc with a high 
mannose glycan which can be used as a starting material to produces other glycoforms. Large 
amount of IgG2 Fc was produced from multiple fermenter runs. Since, the yeast lack the Golgi 
apparatus, further glycan processing in vivo is stopped and therefore the secreted IgG2 Fc 
glycoform was of the high mannose type. The secreted high mannose IgG2 Fc was subjected to 
further purification processes using protein G affinity chromatography, hydrophobic interaction 




glycoprotein from the growth media and produce diglycosylated IgG2 Fc. The purified 
diglycosylated IgG2 Fc of the high mannose type then became a convenient substrate to produce 
the other interesting IgG2 Fc glycoforms such as the hybrid and the fucosylated hybrid IgG2 Fc 
glycoforms using in vitro enzymatic synthesis. The developed in vitro enzymatic synthesis to 
produce different IgG2 Fc glycoforms described in details in chapter 2, provides a detailed 
description on how to produce well-characterized and homogeneous glycoforms not only for 
IgG2 Fc but also for all the other proteins that have N-glycosylation sites (NXS/T sequon) that 
are accessible for N-glycosylation. In this enzymatic synthesis we utilized a series of glycosidase 
and glycosyltransferases such as the bacterial α1,2-mannosidase (BT3990), N-
acetylglucosaminlytransferase-I (GnT-I), and mammalian α1,6-fucosyltransferase (FUT8). In 
this synthesis we also utilized L-fucokinase/guanosine 5'-diphosphate-L-fucose 
pyrophosphorylase (FKP), an enzyme that enabled us to synthesize and purify the natural 
nucleotide sugar, GDP-fucose, that is necessary for FUT8 action and core fucosylation of the 
An297 glycan. With the aid of FKP, we also succeeded in synthesizing and purifying the non-
natural sugar nucleotide, GDP-azidofucose, which enabled functionalization of the Asn297 
glycan for bioorthogonal click reactions to make site-specific antibody drug conjugates as 
described in chapter 3. FUT8, as a key enzyme used in this in vitro enzymatic synthesis was 
produced in a novel way where, for the first time, we produced this mammalian enzyme in a 
modified strain of E.coli in sufficient quantities to do all the required experiments described in 
this work.  
An important Asn297 glycan posttranslational modification is the core fucosylation. 
More than a decade ago, the core fucosylation was shown to reduce the binding of IgG1 to 
FcγRIIIa expressed on the surface of the natural killer cells.
11




correlated with the reduction in IgG1 antibody dependent cellular cytotoxicity (ADCC). This 
finding drew the attention of many pharmaceutical companies and research groups to 
glycoengineer mAb to have low level of core fucose and increase their efficacy through the 
ADCC mode of action. This finding eventually resulted in a successful marketing of 
afucosylated mAb with better efficacy such as mogamulizumab and obinutuzumab for treating 
different types of cancer. However, here we decided to do the reverse, i.e. increasing the level of 
core fucose within the Asn297 glycan of IgG2 subclass. Since, IgG2 has lower effector functions 
dictated by its lower binding affinities to Fcγ receptors and the complement protein C1q, our 
goal was to reduce the binding more, especially to FcγRIIIa, to make a more silent IgG2 Fc. 
Therefore, we utilized the developed enzymatic synthesis for scaling up the production of the 
homogeneous fully fucosylated IgG2 Fc and compare it head to head with the afucosylated IgG2 
Fc. The study was also designed to test the effect of adding core fucose to Asn297 glycan on the 
conformation and stability of IgG2 Fc using biophysical characterization methods. The addition 
of core fucose resulted in a significant reduction (~ 13-fold) of IgG2 Fc binding to FcγRIIIa 
compared to the absence of core fucose. Although IgG2 has a weak affinity to this receptor to 
start with, the avidity that can result from clustering of multiple receptors on the surface of the 
immune effector cells upon engagement with the immune complex, can be high enough to 
induce a considerable magnitude of undesirable ADCC.
12
 Therefore, more reduction in the 
monomeric binding through glycoengineering by introducing more core fucose to Asn297 glycan 
would result in more reduction in any undesirable ADCC. Interestingly, the presence or absence 
of core fucose did not change the binding of IgG2 to FcγRIIa-R131 variant. This result also 
suggests that IgG2 has a different mode of interaction to this receptor than IgG1 because binding 




addition of core fucose to IgG2 Fc did not appear to perturb the conformational stability of the 
Fc probed using various biophysical characterization techniques and this means that producing 
highly fucosylated mAb can be acceptable from the stability perspective. Also, during the course 
of in vitro enzymatic synthesis, FUT8 kinetics studies of the transfer of core fucose to free 
glycan compared to Asn297-bound glycan showed about 10-fold differences in KM but same 
Vmax, indicating lower affinity of FUT8 for protein-bound glycan but similar transition states for 
both glycans. This result could also provide additional evidence on the dynamic nature of the 
Asn297 glycan relative to the surrounding protein backbone seen in other studies
13,14
 and may 
also expand our understanding of the role of Asn297 glycan in fine-tuning the antibody 
conformation and effector functions. Our enzyme kinetics studies also showed that Asn297 is 
more accessible site for GnT-I and FUT8 than a second but unusual glycosylation site in the CH3 
domain of IgG2 Fc (i.e. Asn392 site). This difference in glycosylation site accessibility may also 
explain the glycosylation heterogeneity observed among different glycosylation sites on the same 
protein as reported in previous studies and can increase our understanding of glycoproteins 
biosynthesis. 
Since, antibody drug conjugates (ADCs) mode of action relies on the cytotoxicity of the 
payload to eliminate the cancer cells and does not require activation of the effector functions; we 
were also interested in designing ADCs employing human IgG2 subclass as the mAb part of this 
type of products. It has been postulated that elimination of the cell-mediated effector functions 
could increase the ADC specificity and reduce any possible off-target toxicity by the uptake of 
these molecules by the immune effector cells.
15
 Also, current ADC research focuses on reducing 
the heterogeneity of the marketed ADCs and developing new technologies to introduce the 




lysine or cysteine residues using conventional conjugation chemistry. This approach of 
conjugating the payload at specific sites with a defined drug to antibody (DAR) ratio has been 
shown to improve the ADC stability, pharmacokinetics, and eventually increase the safety and 
efficacy of the product.
16,17
 Therefore, we sought to create a specific site of conjugation within 
the Asn297 glycan of the antibody to expand the number of the present technologies of 
producing site-specific ADCs. This specific site was created with the aid of FUT8 as described in 
chapter 3. First, our synthetic platform described in chapter 2 enabled us to produce sufficient 
quantity of the afucosylated hybrid IgG2 Fc glycoform that can work as a substrate for FUT8 
since this enzyme requires the presence of unblocked N-acetylglucosamine (GlcNAc) on the 
non-reducing terminal of the glycan. In addition, we were able to produce and purify a modified 
fucose nucleotide sugar (GDP-azidofucose) that can be utilized by FUT8 to transfer the modified 
fucose (6-azido-L-fucose) to the Asn297 glycan of IgG2 Fc. We succeeded in optimizing FUT8 
reaction conditions to produce fully functionalized IgG2 Fc with this azido-modified sugar for 
conjugation with alkyne functionalized compounds through the bioorthogonal azide-alkyne 
cycloaddition (AAC). As a proof of concept to test the accessibility of the created site for 
conjugation reactions, we used three compounds (linkers) functionalized with different types of 
alkyne. The alkynes used needed different reaction conditions to react with the 6-azido-L-fucose 
presents on the Asn297 glycan of IgG2 Fc. Also, the alkyne parts of these three compounds 
(linkers) have different physicochemical properties (different size and hydrophobicity) which 
could ultimately affect the final construct properties. The linkers used were one linear alkyne 
linker (Propargyl-PEG4-acid) and two cyclic alkyne likers (BCN-PEG4-acid, and DBCO-PEG5-
acid). The Propargyl linker is the smallest and the least hydrophobic linker among these linkers 




reactions were carried out either through copper(I)-catalyzed azide-alkyne cycloaddition 
(CuAAC) or through strain promoted azide-alkyne cycloaddition (SPAAC) using different types 
of cyclic alkynes. After successful optimization of the conjugation reactions, we produced 
sufficient quantities of homogeneous conjugates to study the effect of the linker type on the 
structural stability, solubility, and binding of these conjugates to Fcγ receptors. As expected, 
these studies showed that the overall conjugate properties can be also affected by the payload 
(linker) properties. For example, the Propargyl-linker did not reduce the solubility 
(thermodynamic activity) of the conjugate while the cyclic linkers, especially the DBCO-linker, 
resulted in some reduction in the conjugate solubility (Thermodynamic activity) measured by 
PEG-precipitation assay. Another effect observed here was the reduction in the DBCO-Fc 
conjugate thermal stability as tested by differential scanning calorimetry and extrinsic 
fluorescence compared to the thermal stability of the naked Fc or the other conjugates. Binding 
to FcγRIIa was also reduced for the DBCO-Fc conjugate compared to the other conjugates 
presumably due to the larger size of the DBCO-linker which can produce more conformational 
changes in the CH2 domain of the Fc. Interestingly,  such reduction in binding to Fcγ receptors 
can be also advantageous when designing ADCs and could reduce any potential off-target 
toxicity. However, the reduction in the DBCO-conjugate stability can be considered marginal 
when comparted to the stability of IgG2 Fc upon the removal of the whole Asn297glycan (i.e. 
deglycosylated Fc). Therefore, conjugation through the core fucose site of Asn297 glycan 
without eliminating this glycan, which could help in mitigating any negative effect due to 
conjugating the usually hydrophobic payloads, would be an attractive approach for the 
production of site-specific ADCs with improved properties. Moreover, combining the site-




reaction conditions and the experimental setup followed, could provide a powerful approach to 
screen for different linkers/ linker-payloads at different stages of drug development to eventually 
develop ADC with better safety, stability, and efficacy profiles. 
Lastly, the developed enzymatic synthesis described in this work can be extended further 
by producing the other type of glycoforms, especially the galactosylated and sialylated 
glycoforms. This can be done by utilizing other enzymes such as mannosidase II, 
galactosyltransferase, and sialyltransferases as well as the necessary nucleotide sugars for 
reactions catalyzed by these enzymes. These terminal sugars in the Asn297 glycan of IgG1 
subclass have been shown to affect the antibody effector functions where sialic acid mediate 
anti-inflammatory effect, while the presence or absence of galactose can affect the antibody 
interaction with the complement system. On the other hand, the novel site-specific 
functionalization of IgG2 Fc at Asn297 glycan described here using FUT8 can be used to 
functionalize a suitable full-length IgG2 with certain specificity to tumor cells. The 
functionalization of IgG2 can be then followed by conjugating different types of toxic payloads 
connected to different linkers to produce site-specific ADCs that can be tested in cell-based 
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 Two appendices are attached to this dissertation where appendix A provides 
supplementary information for Chapter 2 while appendix B provides supplementary information 




Figure A1. SDS-PAGE analysis under reducing conditions using 12% gels of IgG2 Fc variants 
expressed in Pichia pastoris and purified by protein G affinity chromatography. Lane 1 is IgG2 
Fc-(N297, N392) which has a second N- glycosylation site at Asn392 and shows three bands (di-
glycosylated, mono-glycosylated, and non-glycosylated Fc monomers from top to bottom) on the 
gel depending on the extent of site occupancy of these two glycosylation sites. Lane 2 is for IgG2 
Fc-(N297, K392) which has only the consensus Asn297 N-glycosylation site and shows only two 
bands (no di-glycosylated Fc monomer) on the gel depending on whether this site is occupied 










Figure A2. Removal of phosphorylated IgG2 Fc fractions from IgG2 Fc expressed in OCH1 
deleted strain of Pichia pastoris using weak cation exchange (WCX). Intact protein mass spectra 
under reducing conditions of:  A) IgG2 Fc purified only by protein G chromatography from the 
expression media. The encircled peak corresponds to the mass of non-glycosylated Fc monomer; 
B) IgG2 Fc obtained by further purification using HIC (removing hemiglycosylated Fc); C, D, 
and E) represent earlier, intermediate, and later fractions in the elution of IgG2 Fc from the WCX 















Figure A3. Western blot analysis showing different results of FUT8 expression in SHufflle T7 Express E. 
coli using different plasmid constructs. Mouse anti-histidine6-tag antibody and goat anti-mouse alkaline 
phosphatase antibody were used as the primary and secondary antibodies, respectively. The histidine 
tagged proteins were visualized using 1-Step™ NBT/BCIP color development substrate. Lane 1 shows 
two histidine6-tagged proteins with known molecular weight used as references. The rest of labels are 
shown above the lanes. The calculated molecular weights of FUT8-H6 and MBP-FUT8-H6 are 58 kDa and 
100.5 kDa, respectively. Enzyme from lane 9 was used in all subsequent experiments that required FUT8 
in this study. 
Note: Maltose binding protein (MBP) fusion to FUT8 was tried at the beginning to make FUT8 in the SHuffle T7 














Figure A4. SDS-PAGE analysis under reducing conditions using 12% gels of different IgG2 Fc 
glycoforms. Lane 1 is high mannose glycoform. Lane 2 is Man5 glycoform. Lane 3 is GlcNAcMan5 
(hybrid) glycoform. Lane 4 is GlcNAcMan5F (Fuc(+) hybrid) glycoform. Lane 5 is EndoH-digested 
glycoform. Lane 6 is PNGase F- digested Fc. 
  












Figure A5. Using biolayer interferometry (BLI) to check for biotinylation of Fcγ receptors  
through sortase-mediated ligation. During phase 1, PBS checked against a pre-hydrated 
streptavidin biosensor. During phase 2, either the biotinylated Fcγ receptor (purple sensorgram) 
or non-biotinylated Fcγ receptor (orange sensorgram) were checked for their association ability 
to streptavidin biosensors. Phase 3 is switching back to PBS. The experiment indicated that 
sortase-mediated ligation reaction resulted in biotinylating the receptor for immobilization onto 
the surface of the biosensor. However, there was no detectable level of immobilization of the 














Figure A6. Distorted biolayer interferometry (BLI) binding sensorgram for binding of the 
concentrated Fuc(+) hybrid IgG2 Fc glycoform (180 µM) to FcγRIIIa-V158. Upper sensorgram 






























 run 0.33 7.30 2.18 × 10
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Average 3.55 8.58 2.42 × 10
3 




Calculated via error propagation calculator using the kinetic rate constants 
Figure A7. BLI sensorgrams for the binding Fuc(+) IgG2 Fc glycoform to FcγRIIIa-V158 using 
70 µM Fc concentration and subsequent calculation of the binding constants from this 
interaction. The binding at 70 µM was repeated three times as shown in the above sensorgrams 






Production of IgG2 Fc with truncated Asn297 glycans for stability (DSC) studies 
Other IgG2 Fc glycosylation variants were also produced in this study using in vitro 
enzymatic truncation reactions and these glycoforms are the deglycosylated IgG2 Fc, and an 
IgG2 Fc that bears only the first GlcNAc in its Asn297 glycosylation site (GlcNAc-IgG2 Fc). 
The deglycosylated IgG2 Fc was produced by treating high mannose IgG2 Fc with PNGase F 
followed by protein G affinity purification, while the GlcNAc-IgG2 Fc was produced by treating 
high mannose IgG2 Fc with Endoglycosydase H followed by protein G affinity purification. A 
total of about 20 mg of each of these truncated IgG2 Fc glycoforms were produced and their 




Figure AA1. Intact protein mass spectra under reducing conditions of:  a) EndoH-digested IgG2 
Fc; b) PNGase F-digested IgG2 Fc. Both of these forms of truncated Fcs were purified from the 












IgG2 Fc expression construct 
A cDNA of a human IgG2 heavy chain constant region (plasmid MGC-71314) was 
obtained from the mammalian gene collection 
1
 and utilized as a template for PCR amplification 
of human IgG2 Fc encoding DNA (C226-K447) using 5'-
ggcccgctcgagaaaagatgcccaccgtgcccagcacca-3' as a forward primer and 5'-gggcccgcggcggccgc 
tcatttacccggagacagggagag-3' as a reverse primer.
2–4
 The resulting PCR product and the plasmid 
pPICZα A (EasySelect
TM 
Pichia Expression Kit, Invitrogen) were then digested with XhoI and 
NotI restriction endonucleases. T4 DNA ligase was used to ligate the cut PCR product into the 
plasmid and the ligation product was transformed into electrocompetent Top10F’ E. coli. 
Selection of positive colonies was done using LB plates containing zeocin, and plasmid DNA 
from positive colonies was submitted for DNA sequencing to confirm correct insertion of IgG2 
Fc DNA. The resulting construct, named pIgG2 Fc-(N297, N392), was linearized by SacI 
endonuclease and transformed into an electrocompetent, OCH1-deleted strain of SMD1168 
Pichia pastoris produced previously in our laboratory.
5
 Positive yeast colonies for recombinant 





Site-directed mutagenesis to produce IgG2 Fc glycosylation site variants 
Different IgG2 Fc glycosylation site variants (Figure 1, Chapter 2) were produced in this 
study using the cDNA of human IgG2 heavy chain (plasmid MGC-71314) obtained from the 
mammalian gene collection.
1
 The plasmid MGC-71314 codes for an unusual IgG2 Fc 
polymorphism, Asn392. This polymorphism results in an additional N-linked glycosylation site 
in the CH3 domain of IgG2 Fc in addition to the conserved Asn297 glycosylation site located in 
the CH2 domain.
2
 This results in an IgG2 Fc with two glycosylation sites, one at Asn297 and the 
other at Asn392. While this is a naturally occurring polymorphism, it is not the accepted 
consensus sequence for IgG2 Fc.
2
 Therefore, site-directed mutagenesis was conducted with 
primers 5’-gcagccggagaacaactacaagaccacacctcc-3’ and 5’-ggaggtgtggtcttgtagttgttctccggctgc-3’ 
using the pIgG2 Fc-(N297, N392) plasmid as template to convert the asparagine at position 392 
to a lysine to match consensus sequence and produce plasmid pIgG2 Fc-(N297, K392), hereby 
referred to as pIgG2 Fc to reflect it being the consensus sequence. In addition, to study the effect 
of glycosylation sites on FUT8 enzyme kinetics, an additional glycosylation site variant was 
produced where the original pIgG2 Fc-(N297, N392) plasmid was mutated using primers 5'-
cacacggaacgtgctttggaactgctcctcccg-3' and 5'-cgggaggagcagttccaaagcacgttccgtgtg-3' to produce an 
IgG2 Fc variant where the asparagine at position 297 has been mutated to a glutamine, resulting 
in the plasmid pIgG2 Fc-(Q297, N392). Both plasmids pIgG2 Fc and pIgG2 Fc-(Q297, N392) 






Expression and purification of IgG2 Fc 
 IgG2 Fc was expressed in an OCH1 deleted strain of Pichia pastoris, using a BioFlo 415 
fermenter (Eppendorf) on a 7 liter scale as described previously by Okbazghi et al.
6
 During 
fermentation, glycerol is used first to build up the yeast biomass followed by methanol feeding to 
induce IgG2 Fc expression from the IgG2 Fc gene cloned downstream to the AOX1 promoter. 
The expressed IgG2 Fc, which is secreted into the growth media, was purified by protein G 
affinity chromatography. In this purification, the media was centrifuged and filtered and then 
loaded into a protein G column (20-ml bed volume) equilibrated with 10 column volumes (CV) 
of 20 mM potassium phosphate buffer, pH 6.0. The column was then washed with 5 CV using 
column washing buffer (20 mM potassium phosphate buffer pH 6.0 containing 500 mM NaCl) 
and then with 5 CV using the same buffer but without NaCl. The protein was eluted with 100 
mM glycine buffer, pH 2.7 and the protein solution was immediately neutralized using 1M Tris 
HCl buffer, pH 9.0. Using this procedure, about 50 mg of IgG2 Fc is obtained from 1-L 
fermentation media. Three 7-L fermentations were conducted to produce about 1g of the IgG2 Fc 
used in these studies. A second purification step using hydrophobic interaction chromatography 
(HIC) was also carried out to separate hemiglycosylated Fc from the diglycosylated Fc. Briefly, a 
phenyl sepharose™ high-performance resin (GE Healthcare) column (125 ml, packed in house) 
was equilibrated with 5 CV of buffer A ( 20 mM sodium phosphate buffer, pH 7.0 containing 1 
M ammonium sulfate) using an ÄKTAmicro chromatographic system (GE Healthcare). Then, 50 
mg of the protein G- purified IgG2 Fc pre-dialyzed in buffer A was loaded into the column 
followed by a 2 CV washing step using buffer A. A segmented gradient elution using buffer B 
(20 mM sodium phosphate, pH 7.0) was then applied to the column using three gradient 




(33%-55% buffer B, 3.5 CV), and gradient segment 3 (55%-100% buffer B, 2.0 CV). The elution 
fractions containing the diglycosylated IgG2 Fc (as checked by SDS-PAGE and intact protein 
mass spectrometry) were pooled together and concentrated by an Amicon ultra-15 centrifugal 
filter unit with a resulting yield of 27 mg diglycosylated Fc. Finally, weak cation exchange 
chromatography (WCX) was utilized to further purify IgG2 Fc. In this purification, 50 mg of 
diglycosylated IgG2 Fc was dialyzed in buffer C (20 mM sodium acetate buffer pH 5.8) before 
loading into a Macro-Prep CM ion exchange support (Bio-Rad laboratories) column (100 ml, 
packed in house). The column was then washed with 2 CV of buffer C. Then buffer D (20 mM 
sodium acetate buffer pH 5.8 containing 500 mM NaCl) was used to develop a linear gradient 
(0%-50% buffer D, 10 CV) for elution of IgG2 Fc. Several fractions were collected across the 
eluted Fc peak and checked by Q-TOF LC/MS for intact protein mass (Figure A2). Using this 
WCX, a yield of 26 mg of non-phosphorylated high mannose IgG2 Fc was obtained from the 





Expression and purification of IgG2 Fc-(Q297, N392) 
IgG2 Fc-(Q297, N392) was produced in spinner flasks in a manner similar to that 
described for IgG2 Fc. The protein expression was started by inoculating 2 ml of YPD media 
(1% yeast extract, 2% peptone, 5% glucose) containing 100 µg/mL zeocin antibiotic with the 
transformed yeast. After three days of incubation at 25 °C with shaking, the culture was 
transferred into 50-ml YPD media and incubation continued for three additional days. The 50-ml 
culture was then transferred into 1 L of buffered glycerol-complex media (BMGY) containing 
0.004% histidine and 0.00004% biotin. The yeast growth was continued in 1-L spinner flasks for 
two days to build up the yeast biomass and consume the initially supplied glycerol. IgG2 Fc-
(Q297, N392) expression was then induced by feeding the yeast with methanol. During the 
methanol feeding phase, the yeast was supplied with methanol to a final concentration of 0.5% 
by adding 25 ml of 20% methanol in water solution to each spinner flask every 12 h. Methanol 
feeding continued for 2.5 days and IgG2 Fc-(Q297, N392) was then harvested following the 
same procedure described above for harvesting of IgG2 Fc using protein G affinity 
chromatography. Using this procedure, 140 mg of high mannose IgG2 Fc-(Q297, N392) was 
obtained from the 7-L fermentation. Hydrophobic interaction chromatography was also used as 
described above to isolate the diglycosylated Fc from the hemiglycosylated Fc (Figure AA2). 
The expected masses for the Man8 and Man9 (Man8GlcNAc2 and Man9GlcNAc2) glycoforms of 
high mannose IgG2 Fc-(Q297, N392) are 26556.65 Da and 26718.79 Da, and the observed 












Figure AA2. Characterization of the produced IgG2 Fc-(Q297, N392) variant expressed in 
glycosylation deficient Pichia pastoris A) SDS-PAGE analysis under reducing conditions of 
IgG2 Fc-(Q297, N392). Lane 1 shows the recombinantly expressed Fc in Pichia pastoris after 
purification by protein G affinity chromatography. The upper band represents the mono-
glycosylated Fc chain, while the lower band represents the non-glycosylated Fc chain due to 
incomplete glycosylation site occupancy usually encountered following the expression of the Fc 
in Pichia pastoris. Lane 2 shows IgG2 Fc-(Q297, N392) after removal of the hemiglycosylated 
Fc dimer using hydrophobic interaction chromatography (HIC) described in the methods section 
of the manuscript. The single band in lane 2 represents only the mono-glycosylated Fc chain that 
comes from reducing the diglycosylated Fc dimer. B) Intact protein mass spectra under reducing 
conditions (10 mM dithiothreitol) of the expressed Fc in Pichia pastoris after purification by 
only protein G affinity chromatography ( spectrum 1) and after HIC purification (spectrum 2) 
  









FUT8 expression construct 
A construct was designed to express the soluble catalytic domain of mouse FUT8 
(residues 68 to 575) with a C-terminal histidine6-tag in E. coli. PCR was used to amplify the 
FUT8 DNA sequence from cDNA clone MGC-11418 obtained from the mammalian gene 
collection 
1
 using 5'-ggcccgcatatgcgaataccagaaggccccattgaccagggg-3' as a forward primer and 5'-
ggcccggcggagctcttaatgatgatgatgatgatgtttttcagcttcaggatatgtggg-3' as a reverse primer. The PCR 
product as well as the pET30a vector (Novagen) were digested with NdeI and SacI restriction 
endonucleases. T4 DNA ligase was used to ligate the cut PCR product into the cut plasmid and 
the ligated product was transformed into electrocompetent Top10F’ E. coli cells. Selection of 
positive colonies was done using kanamycin on LB plates and the correct FUT8 DNA sequence 
was confirmed by DNA sequencing.  
FUT8 expression and purification 
A 6-ml Luria Broth (LB) culture containing (50 μg/mL) kanamycin was inoculated with 
the pFUT8/pRARE2-SHuffle T7 Express strain and incubated in a shaker incubator at 30 °C for 
about 12 h. This starting culture was then transferred into 1-L of LB medium and incubated at 37 
°C for few hours with shaking until the O.D. at 600 nm was 1.2. Then FUT8 expression was 
induced with IPTG (0.2 mM) and the culture was incubated with shaking for 16 hours at 16 °C. 
The culture was then centrifuged and the cell pellet was re-suspended in 30 ml of resuspension 
buffer (20 mM Tris pH = 7.8, 300 mM NaCl, 5% glycerol). The cells were disrupted with 
sonication followed by centrifugation at 23700 g for 30 min. The supernatant was then loaded 
into a 5 ml Ni-NTA agarose resin (QIAGEN) column pre-equilibrated with the resuspension 




NaCl, 5% glycerol, 20 mM imidazole) and the enzyme was eluted with 250 mM imidazole. The 
enzyme solution was then dialyzed against 50 mM Tris HCl, pH 7.5 buffer and concentrated by 





General procedure utilizing protein G affinity chromatography for the purification of IgG2 
Fc glycoforms  
 At the end of the chemoenzymatic conversion of IgG2 Fc into the desired IgG2 Fc 
glycoform, the reaction mixture is diluted with 20 mM MES buffer pH 6.2 (equilibration buffer) 
to a final IgG2 Fc concentration of 0.1 mg/ml. Then, the diluted Fc solution is loaded into a 
protein G column (about 20 mg total Fc is loaded into a 10-ml bed volume protein G column), 
pre-equilibrated with equilibration buffer, using a loading flow rate of 6 ml/min. The flow-
through is also loaded into the column to ensure full recovery of the Fc from the reaction 
mixture. The column is then washed with 5 CV of the equilibration buffer followed by 5 CV of 
the equilibration buffer containing 500 mM NaCl. A final wash step using 5 CV of the 
equilibration buffer is also conducted to remove the high concentration of salt. Elution of IgG2 
Fc is accomplished by using 100 mM glycine buffer, pH 2.7 and the protein solution is 





Expression and purification of FKP 
A 6-ml Luria Broth medium (LB) containing kanamycin (50 μg/mL) were inoculated with the 
FKP expressing Rosetta 2 frozen stock and incubated in a shaker incubator at 37˚C for about 12 
h. These three starting cultures were then transferred into 2.8 L culture flask containing 1 liter of 
LB having 50 µg/ml kanamycin and incubated at 37 °C with shaking until O.D.600nm reached 
about 1.5 (usually about 4-6 h).Protein expression was induced with 0.2 mM IPTG at room 
temperature for about 8 h. The culture was then centrifuged and the cell pellets were re-
suspended in 30 ml of resuspension buffer (20 mM Tris pH=7.8, 300 mM NaCl, 5% glycerol) 
after discarding the supernatant. Then, the cells were subjected to a 5 min sonication time at 60% 
amplitude and spun down at 14,000 rpm. The supernatant was then loaded onto a 5 ml Ni-NTA 
agarose resin column pre-equilibrated with the resuspension buffer.  The column was washed 
with 200 mL of resuspension buffer plus 10 mM imidazole. The H6-tagged protein was eluted 
with the suspension buffer containing 250 mM imidazole. Eluted protein was then dialyzed 
against 25 mM HEPES (pH 7.5) buffer. The protein was checked with SDS-PAGE, its 










Production of FcγRIIa receptor variants 
Expression plasmids for producing soluble human FcγRIIa  with a C-terminal 
sortase/histidine6-tag, were constructed by amplifying the cDNA encoding the receptor 
extracellular domain (residues 36 to 214) by PCR using plasmid MGC:23887 (FcγRIIa-H131) 
and MGC:30032 (FcγRIIa-R131) from the mammalian gene collection 
1
 as templates and 5'-
ggcccgctcgagaaaagagctgctcccccaaaggctgtgctg-3' and 5'-
ggcccggcgcgcggccgcttaatgatgatgatgatgatgtccacctccagtttctggcaatgaagagctgcccatgctgggcac-3' as 
PCR primers. Then the PCR products and pPICZα A plasmid were digested with XhoI and NotI 
restriction endonucleases. T4 DNA ligase was used to ligate the cut PCR product into the 
plasmid then the ligation products were transformed into electrocompetent Top10F’ E. coli. 
Selection of positive colonies was done using LB plates containing 25 µg/ml zeocin. The correct 
DNA sequence for a positive colony was confirmed by DNA sequencing, and each construct was 
then linearized by SacI endonuclease and transformed into an electrocompetent, OCH1-deleted 
strain of SMD1168 Pichia pastoris produced previously in our laboratory.
5
 Positive yeast 
colonies for recombinant protein production were selected on YPD plates containing 100 µg/ml 
zeocin. Expression of FcγRIIa-H131 or FcγRIIa-R131 was then carried out in a 1-L spinner flask 
following the procedure described above for the expression of IgG2 Fc-(Q297, N392). During 
this expression, glycerol was used to build up the yeast biomass while methanol feeding was 
used to induce protein expression. Then, the secreted protein, FcγRIIa-H131, was purified from 
the expression media using Ni-NTA affinity chromatography followed by HIC for further 
purification.
6
 The receptor purity was checked using SDS-PAGE (Figure AA3 below). The 
purified receptors were then subjected to site-specific biotinylation using a sortase-mediated 
ligation reaction described previously for the biotinylation of FcγRIIIa-V158.
6
 Briefly, the 




buffer, pH 7.5. The reaction mixture containing 18 µM FcγRIIa-H131, 1 mM GGG-linker-
Biotin, 3 mM CaCl2, and 5 mM sortase was incubated at room temperature. After 24 hours, the 
reaction was quenched by adding ethylenediaminetetraacetic acid (EDTA) to 15 mM final 




Figure AA3. SDS-PAGE analysis under reducing conditions using 12% gels of Fc gamma 
receptors (FcγRs) expressed in Pichia pastoris and purified by Ni-NTA affinity chromatography 
and hydrophobic interaction chromatography. Lanes 1 represents FcγRIIa-R131 (contains only 
two N-glycosylation sites), lanes 2 represents FcγRIIa-H131 (contains only two N-glycosylation 





Biolayer interferometry (BLI) binding experiment 
Before starting the binding experiments, the receptors (FcγRIIa-H131, FcγRIIa-R131, or 
FcγRIIIa-V158) and the analytes (different IgG2 Fc glycoforms) were dialyzed in PBS (50 mM 
sodium phosphate, 150 mM NaCl, pH 7.4). In these binding experiments, streptavidin biosensors 
(Pall ForteBio LLC) were chosen for the immobilization of the receptors while the studied IgG2 
Fc glycoform was kept in solution. First, the biosensor is hydrated in PBS buffer for 10 min and 
then followed by incubation in PBS buffer containing 1 mg/ml casein to block any non-specific 
interaction on the surface of the biosensor. The biotinylated receptor is then immobilized on the 
biosensor to 1 nm response level above the baseline using 0.2 µM receptor solution. A new 
baseline was established by placing PBS buffer containing 1 mg/ml casein in the sample holder 
and incubation for 30 s. The analyte (IgG2 Fc) is then placed in the sample holder to initiate the 
association phase (30 s). At the end of this association phase the analyte tube is replaced by a 
tube containing PBS to obtain the dissociation phase (30 s) as shown in Figure AA4 below. Four 
different concentrations of each IgG2 Fc glycoform were used in each binding experiment and 
each binding experiment was repeated three times. The association rate constant and the 
dissociation rate constant (ka and kd, respectively) as well as the equilibrium dissociation constant 
(KD) at 25°C were then calculated by fitting the binding sensorgrams from these different 
concentrations using the global fit function of BLItz Pro software. In case of binding of the 
hybrid and the Fuc(+) hybrid IgG2 Fc glycoforms to FcγRIIIa-V158, the following Fc 
concentrations of each glycoform were used: 17.5, 35, 52.5, and 70 µM. In the case of binding of 
these different glycoforms to FcγRIIa-H131 the following Fc concentrations were used: 0.9, 1.9, 
3.8, and 7.6 µM. In the case of binding of these different glycoforms to FcγRIIa-R131 the 







Figure AA4. Representative sensorgrams for the binding experiments of IgG2 Fc glycoforms 
interacting with Fc gamma receptors (FcγRs) using biolayer interferometry (BLI). In this 
particular binding experiment, hybrid IgG2 Fc glycoform, at four different concentrations, was 
allowed to bind to FcγRIIa-H131 immobilized on a streptavidin biosensor for the determination 
of kinetic rate constants (ka and kd) and the equilibrium dissociation constant (KD) of the 










Chemoenzymatic synthesis and purification of GDP-fucose for α1,6-fucosyltransferase 
(FUT8) activity assay and kinetic measurements 
Pure GDP-fucose was prepared based on a protocol described in the literature 
7
 with 
some modifications and the synthesis was followed up using a previously described method of 
ion-pair reversed-phase HPLC.
8
 400 µl of FKP (about 1.5 mg) was added into 4-ml solution 
containing 100 mM HEPES buffer pH 7.5, 5 mM ATP, 2.5 mM GTP, 10 mM L-fucose, and 10 
mM MgCl2. The reaction was incubated at 28 °C for about 3 hours, and then 15 µl (3 units) of 
yeast inorganic pyrophosphatase (Sigma-Aldrich) was added to the reaction mixture and 
incubated for 9 additional hours. The addition of yeast inorganic pyrophosphatase resulted in 
converting all of GTP into GDP-fucose (Figure AA5). Then 10 units of alkaline Phosphatase 
(CIP, from New England BioLabs) were added to simplify subsequent GDP-fucose purification 
and the reaction was incubated for 4 additional hours. The reaction was then boiled for 5 minutes 
and chilled immediately on ice followed by centrifugation. The supernatant was then 
concentrated in to 1-ml volume by the mean of rotary evaporator and loaded on a Bio-Gel P-2 
(Bio-Rad) column using deionized water as a mobile phase. Several fractions were collected and 
tested for pure GDP-fucose content. The fractions containing pure GDP-fucose were pooled 
together and concentrated by the rotary evaporator. The purified GDP-fucose (Figure AA5) was 






Figure AA5. Ion-pair reversed-phase HPLC for monitoring of the synthesis and purification of 
GDP-fucose through FKP mediated chemoenzymatic synthesis (Zhao et al. 2010). Hypersil™ 
ODS C18 column (120 A°, 5 µm, 4.6 mm X 250 mm, ThermoScientific) was used in this 
analysis. Buffer A was 100 mM potassium phosphate buffer at pH 6.4 containing 8 mM 
tetrabutylammonium hydrogen sulfate (Sigma-Aldrich). Buffer B was composed of 70% buffer 
A plus 30% acetonitrile. The elution gradient was as following: 100% buffer A for 8 min, 0-77% 
buffer B for 8 min, 77-100% buffer B for 1 min, 100% buffer B for 4 min, 100%-0% buffer B 
for 1 min, and finally 100% buffer A for 8 min to re-equilibrate the column. The flow rate was 
1.3 ml/min, the UV detector was set at 254 nm, and the column temperature was 40 °C. The 
above chromatograms are: A) FKP reaction mixture at the beginning of the reaction B) Same 
reaction mixture by the end of the reaction at which all GTP is converted into GDP-fucose C) 












Production of free GlcNAcMan5GlcNAc2 (hybrid) glycan for FUT8 assays 
The GlcNAcMan5GlcNAc2 hybrid N-glycan was produced from the 
GlcNAcMan5GlcNAc2 (hybrid) IgG2 Fc glycoform prepared as described elsewhere in this 
manuscript. The hybrid N-glycan was released from the Fc using PNGase F. Since, the Fc dimer 
has two N-glycans conjugated to it, the resulting concentration of the free glycan is twice the 
starting concentration of the Fc. The complete release of the glycan from the Fc was confirmed 
by mass spectrometry and SDS-PAGE gel (Figure AA6 below) 
 
Figure AA6. SDS-PAGE analysis using 12% gel showing the complete conversion of 
glycosylated IgG2 Fc (lane 1) into deglycosylated IgG2 Fc (lane 2) and release of Asn297 N-
glycan after digestion with PNGase F enzyme. 
  




SDS-PAGE and western blotting 
SDS-PAGE was performed as previously described 
9
 using 12% gels and a 3X reducing 
sample loading buffer (240 mM Tris HCl pH 6.8, 6% SDS, 30% glycerol, 2.3 M 2-
Mercaptoethanol, and 0.04% bromophenol blue). For western blotting, the samples were also run 
on 12% SDS-PAGE then the resolved proteins on the gel were transferred into a PVDF 
membrane (BioRad Immun-Blot membrane for protein blotting) using BIO-RAD Trans-Blot 
Turbo Transfer System. The membrane was then blocked with 5% fat free milk in TTSB (20 
mM Tris HCl, 500 mM NaCl, 0.05% Tween 20, pH 7.5 buffer). After washing with TTSB, the 
membrane was incubated with mouse anti-histidine6-tag antibody as the primary antibody then 
with goat anti-mouse alkaline phosphatase secondary antibody. The histidine tagged proteins 
were then visualized on the membrane using 1-Step™ NBT/BCIP color development substrate 
from ThemoFisher Scientific.  
Intact protein mass spectrometry 
Intact protein mass was determined by injecting 15 µl of protein samples at 
concentrations of approximately 0.3 mg/ml under reducing conditions (10 mM dithiothreitol) 
into a reverse phase C4 column, 50 mm, 4.6 mm I.D. (Vydac 214 MS, 300 A pore size, 5μm 
particle size) using an Agilent 6520 Accurate-Mass Q-TOF LC/MS equipped with an ESI source. 
Solvent A was composed of 99.9% water, 0.08% formic acid, and 0.02% trifluoroacetic acid, 
while solvent B was composed of 99.9% acetonitrile, 0.08% formic acid, and 0.02% 
trifluoroacetic acid. A gradient elution was developed ranging from 5% B to 90% B within 7 min 
using a flow rate of 0.5 mL/min. Data acquisition was performed using Agilent Mass Hunter 
Acquisition software (Version B.02.00) while data analysis was performed using Agilent Mass 
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Figure B1. Representative time points of the one-pot (three steps) functionalization reaction of 









Measuring the kinase activity of FKP 
A continuous coupled spectrophotometric assay similar to one described previously 
(Gosselin et al. 1994)
1
 was used to compare FKP kinase reaction rate for L-fucose or 6-azido-L-
fucose. In this assay, the FKP reaction progress was followed by measuring ADP production 
with a pyruvate kinase/ lactate dehydrogenase (PK/LDH) coupled system to monitor NADH 
disappearance at 340 nm. This assay was performed in 50 mM HEPES buffer pH 7.5 containing 
ATP (1 mM), L-Fucose or 6-azido-L-fucose ( 1 mM), magnesium chloride (10 mM),  potassium 
chloride (50 mM), phosphoenolpyruvate (0.75 mM), NADH (0.15 mM), 3 U pyruvate kinase 
(PK), and 4.2 U lactate dehydrogenase (LDH). The final volume was 150 µl and the reaction was 
started by the addition of FKP (9 µg) after letting the other components equilibrate for 5 min 
inside the cuvette at 37 °C. The decrease in NADH absorbance at 340 nm with time was 
followed using Evolution 260 Bio UV-visible spectrophotometer (ThermoScientific). The linear 
part of this decrease in NADH absorbance with time (slope) was used to compare FKP reaction 
















General procedure for chemoenzymatic synthesis and purification of GDP-azidofucose  
GDP-azidofucose was synthetized chemoenzymatically from 6-azido-L-fucose using the 
bifunctional enzyme L-fucokinase/guanosine 5'-diphosphate-L-fucose pyrophosphorylase (FKP). 
The synthesis and purification was followed up using ion pair chromatography method described 
in the next section (See also Figures BB1, BB2, and BB3). A 4-ml volume reaction was carried 
out in 100 mM HEPES buffer at pH 7.5. The reaction mixture contained 13 mg (5.9 mM) ATP, 
11 mg (5.2 mM) GTP, 5.2 mg (6.3 mM) 6-azido-L-fucose, and 10 mM MgCl2. The reaction was 
started by adding 1.5 mg FKP and incubated at 28 °C. After six hours, 3 units (15 µl) of yeast 
inorganic pyrophosphatase (Sigma-Aldrich) were added to the reaction mixture and the mixture 
was incubated at the same temperature for three days. Finally, 10 units of alkaline phosphatase 
(CIP, New England BioLabs) were added to the reaction mixture to dephosphorylate any free 
nucleotides and simplify subsequent size exclusion chromatography-based purification. After 16 
hours of adding CIP, the reaction mixture was boiled for 5 minutes and chilled immediately on 
ice for 15 minutes to precipitate the enzymes used in this reaction and simplify subsequent 
purification. After chilling on ice, the reaction mixture was centrifuged at full speed for 15 
minutes to get rid of the precipitated enzymes. The supernatant was then collected and 
concentrated to 1 ml by the mean of rotary evaporator. To separate the product (GDP-
azidofucose) from the reaction mixture, the supernatant was loaded on a 2.5 cm diameter column 
containing 120 ml Bio-Gel P-2 resin (BioRad) pre-equilibrated with deionized  water. The 
elution was carried out at a flow rate of 0.7 ml/min using deionized water as a mobile phase. The 
UV detector was set at 254 nm and several fractions were collected across the eluted peaks and 




azidofucose were pooled together and concentrated by rotary evaporator and finally stored at -80 
°C.   
Ion-pair reversed-phase HPLC  
An ion-pair reversed-phase HPLC method was developed based on a previous method 
reported by Nakajima et al. (2010)
2
 to control the synthesis and purification of GDP-azidofucose. 
Hypersil™ ODS C18 column (120 A°, 5 µm, 4.6 mm X 250 mm, ThermoScientific) was used in 
this analysis. Buffer A was 100 mM potassium phosphate buffer at pH 6.4 containing 8 mM 
tetrabutylammonium hydrogen sulfate (Sigma-Aldrich). Buffer B was composed of 70% buffer 
A plus 30% acetonitrile. A 30 minutes elution gradient was developed as following: 100% buffer 
A for 8 min, 0-77% buffer B for 8 min, 77-100% buffer B for 1 min, 100% buffer B for 4 min, 
100%-0% buffer B for 1 min, and finally 100% buffer A for 8 min to re-equilibrate the column 
for subsequent sample injection. The flow rate was 1.3 ml/min, the UV detector was set at 254 














Figure BB1. FKP-catalyzed synthesis of GDP-azidofucose as monitored by ion-pair reversed-
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Figure BB2. Ion-pair reversed-phase HPLC monitoring of FKP-catalyzed chemoenzymatic 
synhesis of GDP-azidofucose after 8 and 16 hours of adding calf intestional phosphatass (CIP) to 































Figure B3. Reaction progress of Propargyl-Fc formation via CuAAC followed up by intact 
protein mass spectra showing a clear protein oxidation with time. 
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Figure B4. Effect of adding1 mM  arginine on the CuAAC reaction. 
  
Starting material (AzFuc-Fc) 









Figure B5. Effect of adding1 mM  methionine on the CuAAC reaction. 
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Figure B6. Using Cu(I)Br instead of CuSO4/Sodium ascorbate in CuAAC reaction. 
  









Figure B7. Combination of EDTA quenching and ultrafiltration to prevent protein oxidation 
during CuAAC reaction. 
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Figure B8. Deglycosylation of DBCO-Fc and BCN-Fc conjugates using PNGase F to conform 
the site of conjugation. 
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Figure B9. Dynamic light scattering (DLS) intensity-derived size distribution plot of IgG2 Fc 








Figure B10. Far-UV circular dichroism spectra of Fc variants in 20 mM phosphate buffer (pH 
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